
Article

Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study

Graphical abstract



Authors

Jan Moritz Niehues, Philip Quirke, Nicholas P. West, ..., Alexander Brobeil, Michael Hoffmeister, Jakob Nikolas Kather

Correspondence

jakob-nikolas.kather@alumni.dkfz.de

In brief

Niehues et al. evaluate deep-learningbased prediction for MSI, *BRAF*, *KRAS*, *NRAS*, and *PIK3CA* biomarker status in colorectal cancer from histopathology slides. They evaluate the performances of trained models in a realistic setting on a large independent patient cohort and find that attention-based multiple-instance learning outperforms all other approaches.

Highlights

- Deep learning can predict MSI and *BRAF* status from routine pathology slides
- Predictions for KRAS, NRAS, and PIK3CA mutations are below clinical-grade performance
- Multi-input models generalize better for BRAF biomarker prediction







Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study



Jan Moritz Niehues,^{1,2} Philip Quirke,³ Nicholas P. West,³ Heike I. Grabsch,^{3,4} Marko van Treeck,^{1,2} Yoni Schirris,^{1,5,6} Gregory P. Veldhuizen,^{1,2} Gordon G.A. Hutchins,³ Susan D. Richman,³ Sebastian Foersch,⁷ Titus J. Brinker,⁸ Junya Fukuoka,^{9,10} Andrey Bychkov,¹⁰ Wataru Uegami,¹⁰ Daniel Truhn,¹¹ Hermann Brenner,^{12,13,14} Alexander Brobeil,^{15,16} Michael Hoffmeister,¹² and Jakob Nikolas Kather^{1,2,3,17,18,19,*}

¹Else Kroener Fresenius Center for Digital Health, Technical University Dresden, 01307 Dresden, Germany

²Department of Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany

³Pathology & Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK

⁴Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, 6229 HX Maastricht, the Netherlands

⁵Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands

⁶University of Amsterdam, 1012 WP Amsterdam, the Netherlands

⁷Institute of Pathology, University Medical Center Mainz, 55131 Mainz, Germany

⁸Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

⁹Department of Pathology Informatics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan

¹⁰Department of Pathology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan

¹¹Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, 52074 Aachen, Germany

¹²Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

¹³Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany

¹⁴German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

¹⁵Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany

¹⁶Tissue Bank, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany

¹⁷Department of Medicine I, University Hospital Dresden, 01307 Dresden, Germany

¹⁸Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany
¹⁹Lead contact

*Correspondence: jakob-nikolas.kather@alumni.dkfz.de https://doi.org/10.1016/j.xcrm.2023.100980

SUMMARY

Deep learning (DL) can predict microsatellite instability (MSI) from routine histopathology slides of colorectal cancer (CRC). However, it is unclear whether DL can also predict other biomarkers with high performance and whether DL predictions generalize to external patient populations. Here, we acquire CRC tissue samples from two large multi-centric studies. We systematically compare six different state-of-the-art DL architectures to predict biomarkers from pathology slides, including MSI and mutations in *BRAF*, *KRAS*, *NRAS*, and *PIK3CA*. Using a large external validation cohort to provide a realistic evaluation setting, we show that models using self-supervised, attention-based multiple-instance learning consistently outperform previous approaches while offering explainable visualizations of the indicative regions and morphologies. While the prediction of MSI and *BRAF* mutations reaches a clinical-grade performance, mutation prediction of *PIK3CA*, *KRAS*, and *NRAS* was clinically insufficient.

INTRODUCTION

Digitized histopathological slides with hematoxylin and eosin (H&E) staining offer a wealth of information that can be quantified and made usable by artificial intelligence (AI), in particular by deep learning (DL) neural networks.¹ DL networks have been developed to predict clinically relevant biomarkers directly from H&E-stained tumor tissue sections.^{2–5} The application of DL for such complex tasks represents a major part of "computa-

tional pathology."^{3,4,6} In colorectal cancer (CRC), DL-based predictability of biomarkers from H&E-stained tissue sections has been reported for microsatellite instability (MSI)⁷⁻¹⁴ and, in smaller studies, for mutations in *BRAF*,^{10,13} *TP53*, *KRAS*, *SMAD4*, *PIK3CA*, and other genes.^{4,15,16} Prediction of MSI or mismatch repair deficiency (dMMR) in CRC is one of the most widely studied tasks¹⁷ due to its high clinical relevance: first, the MSI status may point to hereditary causes of CRC.¹⁸ Second, MSI is the strongest predictor of response to cancer





MSI QUASAR QUASAR attMIL Ciga 0.90 ± 0.03 0.64 ± 0.09 0.98 ± 0.01 Macenko 2 BRAF QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.24 ± 0.08 0.66 ± 0.01 Macenko 3 KRAS QUASAR QUASAR attMIL Ciga 0.59 ± 0.03 0.48 ± 0.02 0.88 ± 0.01 Macenko 5 MSI QUASAR Macenko 6 MSI QUASAR QUASAR MUB-input Wang 0.49 ± 0.02 0.77 ± 0.07 0.99 ± 0.01 Macenko 6 KRAS QUASAR	Exp.	Target	Train	Test	Algorithm	Feats.	AUROC	AUPRCpos	AUPRCneg	Norm in test
KRAS QUASAR QUASAR INPT n.a. 0.63 ± 0.06 0.72 ± 0.05 Macenko NRAS QUASAR QUASAR INPT n.a. 0.50 ± 0.08 0.41 ± 0.01 0.72 ± 0.05 Macenko MSI QUASAR QUASAR INPT n.a. 0.50 ± 0.00 0.35 ± 0.01 0.93 ± 0.01 Macenko BRAF QUASAR QUASAR attMIL Wang 0.82 ± 0.05 0.35 ± 0.01 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.01 Macenko NRAS QUASAR QUASAR attMIL Wang 0.67 ± 0.07 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.07 0.74 ± 0.07 0.74 ± 0.07 0.74 ± 0.07 0.74 ± 0.07 0.74 ± 0.05 0.64 ± 0.01 Macenko NRS QUASAR QUASAR attMIL Ciga 0.75 ± 0.07 0.74 ± 0.08 0.68 ± 0.01 Macenko NRAS QUASAR QUASAR attMIL Ciga 0.55 ± 0.15 <t< td=""><td></td><td>MSI</td><td>QUASAR</td><td>QUASAR</td><td>INPT</td><td>n.a.</td><td>0.90 ± 0.04</td><td>0.63 ± 0.09</td><td>0.98 ± 0.01</td><td>Macenko</td></t<>		MSI	QUASAR	QUASAR	INPT	n.a.	0.90 ± 0.04	0.63 ± 0.09	0.98 ± 0.01	Macenko
NRAS QUASAR QUASAR INPT n.a. 0.50 + 0.08 0.04 + 0.01 0.57 + 0.01 Macenko PIK3CA QUASAR QUASAR QUASAR attMIL Wang 0.54 + 0.04 0.07 + 0.02 0.95 + 0.01 Macenko BRAF QUASAR QUASAR attMIL Wang 0.52 + 0.01 0.56 + 0.13 0.58 + 0.01 Macenko KRAS QUASAR QUASAR attMIL Wang 0.52 + 0.12 0.55 + 0.04 0.57 + 0.05 0.04 0.57 + 0.05 0.04 0.57 + 0.05 0.04 0.57 + 0.05 0.04 0.57 + 0.05 0.04 0.57 + 0.05 0.04 + 0.05 0.04 0.05 + 0.01 Macenko BRAF QUASAR QUASAR attMIL Ciga 0.57 + 0.15 0.12 + 0.08 0.65 + 0.01 Macenko BRAF QUASAR QUASAR AttMIL Ciga 0.57 + 0.15 0.12 + 0.08 0.66 + 0.01 Macenko MRAS QUASAR QUASAR MUL-hput Wang 0.52 + 0.13 0.48 + 0.01 Macenk		BRAF	QUASAR	QUASAR	INPT	n.a.	0.74 ± 0.03	0.25 ± 0.06	0.97 ± 0.01	Macenko
PK3CA QUASAR QUASAR INPT n.a. 0.54 ± 0.04 0.07 ± 0.02 0.95 ± 0.01 Macenko MSI QUASAR QUASAR attMIL Wang 0.94 ± 0.02 0.76 ± 0.04 0.98 ± 0.01 Macenko BRAF QUASAR QUASAR attMIL Wang 0.62 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR attMIL Wang 0.67 ± 0.07 0.02 0.96 ± 0.01 Macenko PK3CA QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.22 0.96 ± 0.01 Macenko BRAF QUASAR QUASAR attMIL Ciga 0.59 ± 0.15 0.48 ± 0.05 0.98 ± 0.01 Macenko MSI QUASAR QUASAR attMIL Ciga 0.58 ± 0.15 0.48 ± 0.05 0.98 ± 0.01 Macenko MSI QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.99 ± 0.01 Macenko MRAS QUASAR QUASAR		KRAS	QUASAR	QUASAR	INPT	n.a.	0.63 ± 0.06	0.52 ± 0.07	0.72 ± 0.05	Macenko
MSI QUASAR QUASAR attMIL Wang 0.94 + 0.02 0.76 + 0.04 0.99 + 0.01 Macenko BRAF QUASAR QUASAR QUASAR attMIL Wang 0.82 + 0.05 0.36 + 0.13 0.98 + 0.01 Macenko RRAS QUASAR QUASAR attMIL Wang 0.67 + 0.04 0.97 + 0.01 Macenko Macenko PRASCA QUASAR QUASAR attMIL Ciga 0.67 + 0.07 0.07 + 0.02 0.98 + 0.01 Macenko MSI QUASAR QUASAR attMIL Ciga 0.57 + 0.05 0.64 + 0.09 0.98 + 0.01 Macenko KRAS QUASAR QUASAR attMIL Ciga 0.58 + 0.15 0.24 + 0.08 0.66 + 0.03 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.58 + 0.15 0.12 + 0.08 0.66 + 0.03 Macenko MRAS QUASAR QUASAR multi-input Wang 0.82 + 0.01 0.85 + 0.01 Macenko MRAS QUASAR QUASA		NRAS	QUASAR	QUASAR	INPT	n.a.	0.50 ± 0.08	0.04 ± 0.01	0.97 ± 0.01	Macenko
BRAF QUASAR QUASAR attMIL Wang 0.82 ± 0.05 0.36 ± 0.11 0.98 ± 0.01 Macenko NPAS QUASAR QUASAR attMIL Wang 0.67 ± 0.04 0.57 ± 0.05 0.74 ± 0.05 Macenko PIK3CA QUASAR QUASAR QUASAR attMIL Wang 0.57 ± 0.07 0.07 ± 0.02 0.96 ± 0.01 Macenko BRAF QUASAR QUASAR QUASAR AttMIL Ciga 0.57 ± 0.07 0.24 ± 0.08 0.86 ± 0.01 Macenko BRAF QUASAR QUASAR QUASAR AttMIL Ciga 0.57 ± 0.07 0.24 ± 0.08 0.48 ± 0.05 0.68 ± 0.03 Macenko MATAS QUASAR QUASAR QUASAR RMIL Ciga 0.57 ± 0.17 0.94 ± 0.02 0.98 ± 0.01 Macenko MSI QUASAR QUASAR QUASAR QUASAR QUASAR Multi-input Wang 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07 0.42 ± 0.07		PIK3CA	QUASAR	QUASAR	INPT	n.a.	0.54 ± 0.04	0.07 ± 0.02	0.95 ± 0.01	Macenko
KRAS QUASAR QUASAR attMIL Wang 0.67 + 0.04 0.57 + 0.05 0.74 + 0.05 Macenko MRAS QUASAR QUASAR attMIL Wang 0.52 ± 0.12 0.05 ± 0.01 0.07 ± 0.01 Macenko P/K3CA QUASAR QUASAR attMIL Wang 0.57 ± 0.07 0.24 ± 0.05 0.98 ± 0.01 Macenko BAF QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.24 ± 0.08 0.98 ± 0.01 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.98 ± 0.01 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.96 ± 0.01 Macenko MSI QUASAR QUASAR multi-input Wang 0.48 ± 0.01 0.01 Macenko MARAS QUASAR QUASAR multi-input Wang 0.47 ± 0.07 0.49 ± 0.01 Macenko MRAS QUASAR QUASAR Multi-input Wa		MSI	QUASAR	QUASAR	attMIL	Wang	0.94 ± 0.02	0.76 ± 0.04	0.99 ± 0.01	Macenko
NRAS QUASAR QUASAR attMIL Wang 0.52 ± 0.12 0.05 ± 0.04 0.97 ± 0.01 Macenko P/R3CA QUASAR QUASAR attMIL Wang 0.67 ± 0.07 0.07 ± 0.02 0.96 ± 0.01 Macenko BRAF QUASAR QUASAR attMIL Ciga 0.97 ± 0.07 0.24 ± 0.08 0.96 ± 0.01 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.42 ± 0.08 0.96 ± 0.01 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.98 ± 0.02 Macenko MRAS QUASAR QUASAR multi-input Wang 0.44 ± 0.02 0.77 ± 0.05 0.74 ± 0.05 Macenko MRAS QUASAR QUASAR multi-input Wang 0.64 ± 0.04 0.57 ± 0.07 0.97 ± 0.02 Macenko MRAS QUASAR QUASAR multi-input Wang 0.65 ± 0.04 0.57 ± 0.05 Macenko MRAS QUASAR QUASAR		BRAF	QUASAR	QUASAR	attMIL	Wang	0.82 ± 0.05	0.36 ± 0.13	0.98 ± 0.01	Macenko
PIK3CA QUASAR QUASAR attMIL Wang 0.57 ± 0.07 0.07 ± 0.02 0.98 ± 0.01 Macenko MSI QUASAR QUASAR attMIL Ciga 0.99 ± 0.03 0.64 ± 0.09 0.98 ± 0.01 Macenko KRAS QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.24 ± 0.08 0.98 ± 0.01 Macenko KRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.98 ± 0.01 Macenko MSI QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.98 ± 0.01 Macenko MSI QUASAR QUASAR multi-input Wang 0.49 ± 0.02 0.77 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.07 0.99 ± 0.01 Macenko NRAS QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.01 n.a. NRAS QUASAR QUASAR		KRAS	QUASAR	QUASAR	attMIL	Wang	0.67 ± 0.04	0.57 ± 0.05	0.74 ± 0.05	Macenko
MSI QUASAR QUASAR attMIL Ciga 0.90 ± 0.03 0.64 ± 0.09 0.98 ± 0.01 Macenko BAFF QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.24 ± 0.08 0.98 ± 0.01 Macenko NRAS QUASAR QUASAR attMIL Ciga 0.59 ± 0.03 0.48 ± 0.05 0.99 ± 0.01 Macenko S MSI QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.41 ± 0.02 0.99 ± 0.01 Macenko BAF QUASAR QUASAR multi-input Wang 0.82 ± 0.07 0.43 ± 0.11 0.98 ± 0.01 Macenko BAF QUASAR QUASAR multi-input Wang 0.82 ± 0.07 0.43 ± 0.10 0.98 ± 0.03 Macenko MSI QUASAR QUASAR multi-input Wang 0.62 ± 0.07 0.03 ± 0.02 Macenko MSI QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.09 ± 0.02 Macenko MSI QUASAR QUASAR QUA		NRAS	QUASAR	QUASAR	attMIL	Wang	0.52 ± 0.12	0.05 ± 0.04	0.97 ± 0.01	Macenko
BRAF QUASAR QUASAR attMIL Ciga 0.74 ± 0.07 0.24 ± 0.08 0.96 ± 0.01 Macenko 8 KRAS QUASAR QUASAR attMIL Ciga 0.59 ± 0.03 0.48 ± 0.05 0.69 ± 0.03 Macenko 9 NRAS QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.02 0.98 ± 0.01 Macenko 6 MSI QUASAR QUASAR multi-input Wang 0.64 ± 0.02 0.77 ± 0.07 0.99 ± 0.01 Macenko 8 RAAS QUASAR QUASAR multi-input Wang 0.62 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko 9 NRAS QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.09 ± 0.01 0.45 ± 0.03 Macenko 9 NRAS QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.09 ± 0.01 0.45 ± 0.03 Macenko 9 NRAS QUASAR QUASAR clinical data only n.a. 0.77 ± 0.08 <td>)</td> <td>РІКЗСА</td> <td>QUASAR</td> <td>QUASAR</td> <td>attMIL</td> <td>Wang</td> <td>0.57 ± 0.07</td> <td>0.07 ± 0.02</td> <td>0.96 ± 0.01</td> <td>Macenko</td>)	РІКЗСА	QUASAR	QUASAR	attMIL	Wang	0.57 ± 0.07	0.07 ± 0.02	0.96 ± 0.01	Macenko
KRAS QUASAR QUASAR attMIL Ciga 0.59 ± 0.03 0.48 ± 0.05 0.69 ± 0.03 Macenko MRAS QUASAR QUASAR attMIL Ciga 0.55 ± 0.15 0.04 ± 0.02 0.98 ± 0.01 Macenko MSI QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.04 ± 0.02 0.79 ± 0.01 Macenko BRAF QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.48 ± 0.03 0.37 ± 0.02 Macenko NRAS QUASAR QUASAR Clinical data only n.a. 0.80 ± 0.03 0.37 ± 0.05 0.68 ± 0.01 n.a. RFAF QUASAR QUASAR Clinical data only n.a. 0.54 ± 0.13 0.06 ± 0.07 0.98 ± 0.01 n.a. NRAS QUASAR <t< td=""><td>I</td><td>MSI</td><td>QUASAR</td><td>QUASAR</td><td>attMIL</td><td>Ciga</td><td>0.90 ± 0.03</td><td>0.64 ± 0.09</td><td>0.98 ± 0.01</td><td>Macenko</td></t<>	I	MSI	QUASAR	QUASAR	attMIL	Ciga	0.90 ± 0.03	0.64 ± 0.09	0.98 ± 0.01	Macenko
NRAS QUASAR QUASAR attMIL Ciga 0.58 ± 0.15 0.04 ± 0.02 0.98 ± 0.01 Macenko MK3CA QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.96 ± 0.02 Macenko BRAF QUASAR QUASAR multi-input Wang 0.94 ± 0.02 0.77 ± 0.07 0.99 ± 0.01 Macenko BRAF QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko P/R3CA QUASAR QUASAR multi-input Wang 0.52 ± 0.07 0.95 ± 0.03 Macenko MSI QUASAR QUASAR Clinical data only n.a. 0.87 ± 0.07 0.96 ± 0.02 n.a. SRAF QUASAR QUASAR Clinical data only n.a. 0.57 ± 0.05 0.61 ± 0.07 0.98 ± 0.01 n.a. RAFA QUASAR QUASAR	2	BRAF	QUASAR	QUASAR	attMIL	Ciga	0.74 ± 0.07	0.24 ± 0.08	0.96 ± 0.01	Macenko
PIK3CA QUASAR QUASAR attMIL Ciga 0.57 ± 0.15 0.12 ± 0.08 0.96 ± 0.02 Macenko MSI QUASAR QUASAR QUASAR Multi-Input Wang 0.94 ± 0.02 0.77 ± 0.07 0.99 ± 0.01 Macenko BRAF QUASAR QUASAR Multi-Input Wang 0.82 ± 0.07 0.43 ± 0.11 0.98 ± 0.05 0.97 ± 0.02 Macenko KRAS QUASAR QUASAR QUASAR Multi-Input Wang 0.49 ± 0.18 0.08 ± 0.07 0.97 ± 0.02 Macenko MSI QUASAR QUASAR QUASAR CIUASAR CIInical data only n.a. 0.80 ± 0.03 0.96 ± 0.01 n.a. BRAF QUASAR QUASAR CIInical data only n.a. 0.50 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. NRAS QUASAR QUASAR CIInical data only n.a. 0.54 ± 0.01 0.84 ± 0.01 0.84 ± 0.01 0.84 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.54 ± 0.01 <td>3</td> <td>KRAS</td> <td>QUASAR</td> <td>QUASAR</td> <td>attMIL</td> <td>Ciga</td> <td>0.59 ± 0.03</td> <td>0.48 ± 0.05</td> <td>0.69 ± 0.03</td> <td>Macenko</td>	3	KRAS	QUASAR	QUASAR	attMIL	Ciga	0.59 ± 0.03	0.48 ± 0.05	0.69 ± 0.03	Macenko
MSI QUASAR QUASAR multi-input Wang 0.94 ± 0.02 0.77 ± 0.07 0.99 ± 0.01 Macenko BRAF QUASAR QUASAR multi-input Wang 0.82 ± 0.07 0.43 ± 0.11 0.98 ± 0.05 Macenko KRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko P/K3CA QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.07 0.97 ± 0.02 Macenko MSI QUASAR QUASAR QUASAR Clinical data only n.a. 0.77 ± 0.06 0.24 ± 0.07 0.98 ± 0.01 n.a. n.a. NRAS QUASAR QUASAR QUASAR QUASAR QUASAR QUASAR QUASAR QUASAR DACHS NRH n.a. 0.54 ± 0.04 0.98 ± 0.01 n.a. MSI QUASAR DACHS INPT	Ļ	NRAS	QUASAR	QUASAR	attMIL	Ciga	0.58 ± 0.15	0.04 ± 0.02	0.98 ± 0.01	Macenko
BRAF QUASAR QUASAR multi-input Wang 0.82 ± 0.07 0.43 ± 0.11 0.98 ± 0.01 Macenko KRAS QUASAR QUASAR Multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR QUASAR Multi-input Wang 0.49 ± 0.11 0.97 ± 0.02 Macenko MSI QUASAR QUASAR QUASAR Clinical data only n.a. 0.80 ± 0.03 0.37 ± 0.05 0.95 ± 0.01 n.a. BRAF QUASAR QUASAR QUASAR Clinical data only n.a. 0.77 ± 0.08 0.24 ± 0.07 0.96 ± 0.02 n.a. BRAF QUASAR QUASAR QUASAR QUASAR Clinical data only n.a. 0.54 ± 0.13 0.66 ± 0.07 0.96 ± 0.01 n.a. MKAS QUASAR DACHS INPT n.a. 0.54 ± 0.04 0.98 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.27 ± 0.01 0.88 ± 0.00 <t< td=""><td>5</td><td>PIK3CA</td><td>QUASAR</td><td>QUASAR</td><td>attMIL</td><td>Ciga</td><td>0.57 ± 0.15</td><td>0.12 ± 0.08</td><td>0.96 ± 0.02</td><td>Macenko</td></t<>	5	PIK3CA	QUASAR	QUASAR	attMIL	Ciga	0.57 ± 0.15	0.12 ± 0.08	0.96 ± 0.02	Macenko
KRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.07 0.97 ± 0.02 Macenko MSI QUASAR QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.09 ± 0.10 0.55 ± 0.03 Macenko MSI QUASAR QUASAR QUASAR Clinical data only n.a. 0.80 ± 0.03 0.37 ± 0.05 0.96 ± 0.01 n.a. BRAF QUASAR QUASAR CUASAR clinical data only n.a. 0.75 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. NRAS QUASAR QUASAR CUASAR Clinical data only n.a. 0.54 ± 0.13 0.06 ± 0.07 0.98 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.76 ± 0.02 0.97 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.88 ± 0.01	6	MSI	QUASAR	QUASAR	multi-input	Wang	0.94 ± 0.02	0.77 ± 0.07	0.99 ± 0.01	Macenko
KRAS QUASAR QUASAR multi-input Wang 0.66 ± 0.04 0.57 ± 0.03 0.74 ± 0.05 Macenko NRAS QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.07 0.97 ± 0.02 Macenko NRAS QUASAR QUASAR QUASAR Multi-input Wang 0.52 ± 0.17 0.09 ± 0.10 0.95 ± 0.03 Macenko MSI QUASAR QUASAR CUASAR CUASAR CUASAR 0.68 ± 0.03 0.24 ± 0.07 0.95 ± 0.02 n.a. RAR QUASAR QUASAR CUASAR CUASAR CUASAR 0.65 ± 0.04 0.41 ± 0.05 0.62 ± 0.04 n.a. MRAS QUASAR QUASAR CUASAR CINIcia data only n.a. 0.56 ± 0.02 0.97 ± 0.01 n.a. MRAS QUASAR DACHS INPT n.a. 0.66 ± 0.02 0.22 ± 0.01 0.88 ± 0.01 Macenko MSI QUASAR DACHS MIMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.88 ± 0.01 0.01	,	BRAF	QUASAR	QUASAR	multi-input	Wang	0.82 ± 0.07	0.43 ± 0.11	0.98 ± 0.01	Macenko
NRAS QUASAR QUASAR multi-input Wang 0.49 ± 0.18 0.08 ± 0.07 0.97 ± 0.02 Macenko MSI QUASAR QUASAR multi-input Wang 0.52 ± 0.17 0.09 ± 0.10 0.95 ± 0.03 Macenko MSI QUASAR QUASAR clinical data only n.a. 0.80 ± 0.03 0.37 ± 0.05 0.96 ± 0.01 n.a. BRAF QUASAR QUASAR clinical data only n.a. 0.77 ± 0.08 0.24 ± 0.07 0.96 ± 0.01 n.a. NRAS QUASAR QUASAR clinical data only n.a. 0.54 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. NRAS QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.88 ± 0.01 n.a. n.a. MSI QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.98 ± 0.01 Macenko MSI QUASAR DACHS IMTL Wang 0.92 ± 0.01 0.68 ± 0.03 0.99 ± 0.00 Macenko MSI QUASAR DA	3	KRAS	QUASAR	QUASAR	multi-input	Wang	0.66 ± 0.04	0.57 ± 0.03	0.74 ± 0.05	Macenko
MSI QUASAR QUASAR clinical data only n.a. 0.80 ± 0.03 0.37 ± 0.05 0.96 ± 0.01 n.a. 2 BRAF QUASAR QUASAR clinical data only n.a. 0.77 ± 0.08 0.24 ± 0.07 0.96 ± 0.02 n.a. 3 KRAS QUASAR QUASAR clinical data only n.a. 0.50 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. 5 PIK3CA QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. 6 MSI QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. 6 MSI QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.01 Macenko 7 BRAF QUASAR DACHS attMIL Wang 0.92 ± 0.01 0.68 ± 0.02 0.98 ± 0.00 Macenko 8 BRAF QUASAR DACHS attMIL Vang 0.92 ± 0.01 0.72 ± 0.03 0.32 ± 0.05 0.99 ± 0.00	9	NRAS	QUASAR	QUASAR		Wang	0.49 ± 0.18	0.08 ± 0.07	0.97 ± 0.02	Macenko
BRAF QUASAR QUASAR clinical data only n.a. 0.77 ± 0.08 0.24 ± 0.07 0.96 ± 0.02 n.a. 8 KRAS QUASAR QUASAR clinical data only n.a. 0.50 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. 6 NRAS QUASAR QUASAR clinical data only n.a. 0.55 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. 6 NRAS QUASAR QUASAR clinical data only n.a. 0.55 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. 6 MSI QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.00 Macenko 8 MSI QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko 9 BRAF QUASAR DACHS attMIL Wang 0.82 ± 0.01 0.72 ± 0.02 0.98 ± 0.00 Macenko 9 MSI QUASAR DACHS attMIL Wang 0.82 ± 0.01)	РІКЗСА	QUASAR	QUASAR	multi-input	Wang	0.52 ± 0.17	0.09 ± 0.10	0.95 ± 0.03	Macenko
B KRAS QUASAR QUASAR clinical data only n.a. 0.50 ± 0.06 0.41 ± 0.05 0.62 ± 0.04 n.a. NRAS QUASAR QUASAR clinical data only n.a. 0.54 ± 0.13 0.06 ± 0.07 0.98 ± 0.01 n.a. PIK3CA QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.86 ± 0.02 0.54 ± 0.04 0.98 ± 0.00 Macenko BRAF QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.88 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.03 0.99 ± 0.00 Macenko MSI QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko MSI QUASAR		MSI	QUASAR	QUASAR	clinical data only	n.a.	0.80 ± 0.03	0.37 ± 0.05	0.96 ± 0.01	n.a.
NRAS QUASAR QUASAR clinical data only n.a. 0.54 ± 0.13 0.06 ± 0.07 0.98 ± 0.01 n.a. A PIK3CA QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. B MSI QUASAR DACHS INPT n.a. 0.86 ± 0.02 0.54 ± 0.04 0.98 ± 0.00 Macenko B RAF QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.00 Macenko B MSI QUASAR DACHS attMIL Wang 0.92 ± 0.01 0.68 ± 0.03 0.99 ± 0.00 Macenko B BRAF QUASAR DACHS attMIL Wang 0.72 ± 0.03 0.32 ± 0.01 0.97 ± 0.01 Macenko B BRAF QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko B BRAF QUASAR DACHS multi-input Wang 0.82 ± 0.01 0.72	2	BRAF	QUASAR	QUASAR	clinical data only	n.a.	0.77 ± 0.08	0.24 ± 0.07	0.96 ± 0.02	n.a.
First PI/S3CA QUASAR QUASAR clinical data only n.a. 0.59 ± 0.06 0.08 ± 0.02 0.97 ± 0.01 n.a. S MSI QUASAR DACHS INPT n.a. 0.86 ± 0.02 0.54 ± 0.04 0.98 ± 0.01 Macenko BRAF QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Wang 0.92 ± 0.01 0.68 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Ciga 0.72 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko BRAF QU	3	KRAS	QUASAR	QUASAR	clinical data only	n.a.	0.50 ± 0.06	0.41 ± 0.05	0.62 ± 0.04	n.a.
B MSI QUASAR DACHS INPT n.a. 0.86 ± 0.02 0.54 ± 0.04 0.98 ± 0.01 Macenko BRAF QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Wang 0.92 ± 0.01 0.68 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS attMIL Ciga 0.72 ± 0.03 0.32 ± 0.05 0.95 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko BRAF QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 Macenko BRAF QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.01 n.a. MSI QUASAR	1	NRAS	QUASAR	QUASAR	clinical data only	n.a.	0.54 ± 0.13	0.06 ± 0.07	0.98 ± 0.01	n.a.
BRAF QUASAR DACHS INPT n.a. 0.78 ± 0.02 0.22 ± 0.01 0.98 ± 0.00 Macenko B MSI QUASAR DACHS attMIL Wang 0.92 ± 0.01 0.68 ± 0.03 0.99 ± 0.00 Macenko B BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko B MSI QUASAR DACHS attMIL Ciga 0.72 ± 0.03 0.32 ± 0.05 0.95 ± 0.00 Macenko B BRAF QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko B BRAF QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko B BRAF QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 Macenko B BRAF QUASAR DACHS clinical data only n.a. 0.78 ± 0.03 0.22 ±	5	РІКЗСА	QUASAR	QUASAR	clinical data only	n.a.	0.59 ± 0.06	0.08 ± 0.02	0.97 ± 0.01	n.a.
BMSIQUASARDACHSattMILWang0.92 ± 0.010.68 ± 0.030.99 ± 0.00MacenkoBBRAFQUASARDACHSattMILWang0.81 ± 0.010.27 ± 0.020.98 ± 0.00MacenkoBMSIQUASARDACHSattMILCiga0.72 ± 0.030.32 ± 0.050.95 ± 0.00MacenkoBBRAFQUASARDACHSattMILCiga0.73 ± 0.020.18 ± 0.010.97 ± 0.01MacenkoBBRAFQUASARDACHSmulti-inputWang0.92 ± 0.010.72 ± 0.030.99 ± 0.00MacenkoBBRAFQUASARDACHSmulti-inputWang0.85 ± 0.010.35 ± 0.020.98 ± 0.00MacenkoBBRAFQUASARDACHSclinical data onlyn.a.0.80 ± 0.020.28 ± 0.040.97 ± 0.00n.a.BBRAFQUASARDACHSclinical data onlyn.a.0.80 ± 0.020.28 ± 0.040.97 ± 0.01n.a.BBRAFQUASARDACHSclinical data onlyn.a.0.75 ± 0.030.97 ± 0.01n.a.BBRAFQUASARDACHSINPTn.a.0.75 ± 0.030.98 ± 0.01noneBBRAFQUASARDACHSattMILWang0.91 ± 0.010.67 ± 0.030.98 ± 0.01noneBBRAFQUASARDACHSattMILWang0.71 ± 0.050.25 ± 0.090.95 ± 0.01noneBBRAFQUASARDACHSmulti-input <td>3</td> <td>MSI</td> <td>QUASAR</td> <td>DACHS</td> <td>INPT</td> <td>n.a.</td> <td>0.86 ± 0.02</td> <td>0.54 ± 0.04</td> <td>0.98 ± 0.01</td> <td>Macenko</td>	3	MSI	QUASAR	DACHS	INPT	n.a.	0.86 ± 0.02	0.54 ± 0.04	0.98 ± 0.01	Macenko
BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS attMIL Ciga 0.72 ± 0.03 0.32 ± 0.05 0.95 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko MSI QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 n.a. BRAF QUASAR DACHS clinical data only n.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 none MSI QUASAR <t< td=""><td>7</td><td>BRAF</td><td>QUASAR</td><td>DACHS</td><td>INPT</td><td>n.a.</td><td>0.78 ± 0.02</td><td>0.22 ± 0.01</td><td>0.98 ± 0.00</td><td>Macenko</td></t<>	7	BRAF	QUASAR	DACHS	INPT	n.a.	0.78 ± 0.02	0.22 ± 0.01	0.98 ± 0.00	Macenko
BRAF QUASAR DACHS attMIL Wang 0.81 ± 0.01 0.27 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS attMIL Ciga 0.72 ± 0.03 0.32 ± 0.05 0.95 ± 0.00 Macenko BRAF QUASAR DACHS attMIL Ciga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko MSI QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko BRAF QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 Macenko MSI QUASAR DACHS multi-input Wang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 n.a. BRAF QUASAR DACHS clinical data only n.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 none MSI QUASAR <t< td=""><td>3</td><td>MSI</td><td>QUASAR</td><td>DACHS</td><td>attMIL</td><td>Wang</td><td>0.92 ± 0.01</td><td>0.68 ± 0.03</td><td>0.99 ± 0.00</td><td>Macenko</td></t<>	3	MSI	QUASAR	DACHS	attMIL	Wang	0.92 ± 0.01	0.68 ± 0.03	0.99 ± 0.00	Macenko
BRAFQUASARDACHSattMILCiga 0.73 ± 0.02 0.18 ± 0.01 0.97 ± 0.01 Macenko2MSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 Macenko3BRAFQUASARDACHSmulti-inputWang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 Macenko4MSIQUASARDACHSclinical data onlyn.a. 0.80 ± 0.02 0.28 ± 0.04 0.97 ± 0.00 n.a.5BRAFQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.6BRAFQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.6BRAFQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 n.a.7BRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 none8MSIQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 none9BRAFQUASARDACHSattMILWang 0.75 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 none9BRAFQUASARDACHSattMILWang 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 none9BRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 <	Э	BRAF	QUASAR	DACHS	attMIL	Wang	0.81 ± 0.01	0.27 ± 0.02	0.98 ± 0.00	Macenko
AMSIQUASARDACHSmulti-inputWarg 0.92 ± 0.01 0.72 ± 0.03 0.99 ± 0.00 MacenkoBBRAFQUASARDACHSmulti-inputWarg 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 MacenkoMSIQUASARDACHSclinical data onlyn.a. 0.80 ± 0.02 0.28 ± 0.04 0.97 ± 0.00 n.a.BRAFQUASARDACHSclinical data onlyn.a. 0.80 ± 0.02 0.28 ± 0.04 0.97 ± 0.01 n.a.MSIQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.BRAFQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWarg 0.71 ± 0.05 0.25 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.71 ± 0.05 0.95 ± 0.01 noneBRAFQUASARDACHSmulti-inputWarg 0.84 ± 0.02 0.55 ± 0.04 0.96 ± 0.01 noneBRAFQUASARDACHSmulti-inputWarg 0.71 ± 0.05)	MSI	QUASAR	DACHS	attMIL	Ciga	0.72 ± 0.03	0.32 ± 0.05	0.95 ± 0.00	Macenko
BRAFQUASARDACHSmulti-inputWang 0.85 ± 0.01 0.35 ± 0.02 0.98 ± 0.00 MacenkoMSIQUASARDACHSclinical data onlyn.a. 0.80 ± 0.02 0.28 ± 0.04 0.97 ± 0.00 n.a.BRAFQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.MSIQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.BRAFQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.01 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02	1	BRAF	QUASAR	DACHS	attMIL	Ciga	0.73 ± 0.02	0.18 ± 0.01	0.97 ± 0.01	Macenko
MSI QUASAR DACHS clinical data only n.a. 0.80 ± 0.02 0.28 ± 0.04 0.97 ± 0.00 n.a. BRAF QUASAR DACHS clinical data only n.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a. MSI QUASAR DACHS INPT n.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 n.a. BRAF QUASAR DACHS INPT n.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 none BRAF QUASAR DACHS INPT n.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 none BRAF QUASAR DACHS attMIL Wang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 none BRAF QUASAR DACHS attMIL Wang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 none BRAF QUASAR DACHS attMIL Wang 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 none BRAF QUASAR DACHS attMIL Ciga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 none	2	MSI	QUASAR	DACHS	multi-input	Wang	0.92 ± 0.01	0.72 ± 0.03	0.99 ± 0.00	Macenko
BRAFQUASARDACHSclinical data onlyn.a. 0.78 ± 0.03 0.22 ± 0.04 0.97 ± 0.01 n.a.MSIQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneMSIQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneMSIQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneMSIQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneMSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupgUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoMSIBRAFQUASAR/MSI subgroupgUASAR/MSI subgroupattMILWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.01 Macenko	3	BRAF	QUASAR	DACHS	multi-input	Wang	0.85 ± 0.01	0.35 ± 0.02	0.98 ± 0.00	Macenko
AMSIQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.75 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneBRAFQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoBRAFQUASAR/MSSQUASAR/MSSAttMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	1	MSI	QUASAR	DACHS	clinical data only	n.a.	0.80 ± 0.02	0.28 ± 0.04	0.97 ± 0.00	n.a.
AMSIQUASARDACHSINPTn.a. 0.80 ± 0.04 0.33 ± 0.08 0.97 ± 0.01 noneBRAFQUASARDACHSINPTn.a. 0.75 ± 0.03 0.18 ± 0.03 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.75 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSattMILWang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneBRAFQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneBRAFQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoBRAFQUASAR/MSSQUASAR/MSSAttMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	5	BRAF	QUASAR	DACHS	clinical data only	n.a.	0.78 ± 0.03	0.22 ± 0.04	0.97 ± 0.01	n.a.
BMSIQUASARDACHSattMILWang 0.91 ± 0.01 0.67 ± 0.03 0.98 ± 0.00 noneBBRAFQUASARDACHSattMILWang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 noneMSIQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneMSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSIDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSISubgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.02 0.84 ± 0.02 0.84 ± 0.02 0.84 ± 0.02 BRAFQUASAR/MSIQUASAR/MSIattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoMSIBRAFQUASAR/MSSQUASAR/MSSattMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	3	MSI			-	n.a.				none
BRAF QUASAR DACHS attMIL Wang 0.78 ± 0.03 0.26 ± 0.04 0.97 ± 0.00 none MSI QUASAR DACHS attMIL Ciga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 none BRAF QUASAR DACHS attMIL Ciga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 none MSI QUASAR DACHS attMIL Ciga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 none MSI QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 none BRAF QUASAR DACHS multi-input Wang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 none BRAF QUASAR/MSI QUASAR/MSI attMIL Wang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 Macenko Wang BRAF QUASAR/MSS QUASAR/MSS attMIL Wang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	7	BRAF	QUASAR	DACHS	INPT	n.a.	0.75 ± 0.03	0.18 ± 0.03	0.97 ± 0.00	none
MSIQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneMSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.02 0.84 ± 0.02 BRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoBRAFQUASAR/MSSQUASAR/MSSattMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	3	MSI	QUASAR	DACHS	attMIL	Wang	0.91 ± 0.01	0.67 ± 0.03	0.98 ± 0.00	none
MSIQUASARDACHSattMILCiga 0.71 ± 0.05 0.25 ± 0.09 0.95 ± 0.01 noneBRAFQUASARDACHSattMILCiga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 noneMSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.02 0.84 ± 0.02 BRAFQUASAR/MSSI subgroupQUASAR/MSSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoBRAFQUASAR/MSSI subgroupQUASAR/MSSI subgroupattMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko)					Ū				
BRAF QUASAR DACHS attMIL Ciga 0.68 ± 0.06 0.15 ± 0.04 0.96 ± 0.01 none 8 MSI QUASAR DACHS multi-input Wang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 none 8 BRAF QUASAR DACHS multi-input Wang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 none 8 BRAF QUASAR DACHS multi-input Wang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 none 8 BRAF QUASAR/MSI QUASAR/MSI attMIL Wang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 Macenko 9 BRAF QUASAR/MSS QUASAR/MSS attMIL Wang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko)	MSI	QUASAR	DACHS	attMIL	Ciga	0.71 ± 0.05	0.25 ± 0.09	0.95 ± 0.01	none
MSIQUASARDACHSmulti-inputWang 0.92 ± 0.01 0.72 ± 0.02 0.99 ± 0.00 noneBRAFQUASARDACHSmulti-inputWang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 noneBRAFQUASAR/MSI subgroupQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 MacenkoBRAFQUASAR/MSSQUASAR/MSSattMILWang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko						-				
BRAF QUASAR DACHS multi-input Wang 0.84 ± 0.02 0.35 ± 0.04 0.98 ± 0.00 none 4 BRAF QUASAR/MSI QUASAR/MSI attMIL Wang 0.73 ± 0.06 0.63 ± 0.09 0.84 ± 0.03 Macenko 5 BRAF QUASAR/MSS QUASAR/MSS attMIL Wang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	2					-				
BRAFQUASAR/MSI subgroupQUASAR/MSI subgroupattMILWang warg0.73 ± 0.06 0.63 ± 0.090.84 ± 0.03 0.84 ± 0.03Macenko5BRAFQUASAR/MSSQUASAR/MSSattMILWang warg0.66 ± 0.100.12 ± 0.080.98 ± 0.01Macenko	3				•	-				
<i>BRAF</i> QUASAR/MSS QUASAR/MSS attMIL Wang 0.66 ± 0.10 0.12 ± 0.08 0.98 ± 0.01 Macenko	1		QUASAR/MSI	QUASAR/MSI	•	•				
	5	BRAF	QUASAR/MSS	QUASAR/MSS	attMIL	Wang	0.66 ± 0.10	0.12 ± 0.08	0.98 ± 0.01	Macenko

(Continued on next page)

Article



Table 1. Continued											
Exp.	Target	Train	Test	Algorithm	Feats.	AUROC	AUPRCpos	AUPRCneg	Norm in test		
46	MSI	QUASAR/BRAF ^{wt}	QUASAR/BRAF ^{wt}	attMIL	Wang	0.89 ± 0.06	0.57 ± 0.11	0.98 ± 0.02	Macenko		
47	MSI	QUASAR/BRAF ^{mut}	QUASAR/BRAF ^{mut}	attMIL	Wang	0.78 ± 0.15	0.80 ± 0.15	0.79 ± 0.15	Macenko		

If the test set is the same as the training set, then five-fold cross-validation on the patient level was used. AUROCs are given as mean \pm 95% confidence intervals for the five-fold AUC scores. Precision-recall curves for experiments 32 and 33 can be found in Figure S3. Domain shift plots for experiments 6, 7, 28, and 29 can be found in Figure S4 and for experiments 16, 17, 32, and 33 in Figure S5, respectively. Ex., experiment number; Feats., features; Norm, color normalization of the test set (training set was always color normalized).

immunotherapy.¹⁹ Third, MSI has an important role in the management of patients with CRC, for example in the decision whether to prescribe adjuvant chemotherapy.²⁰

Building on evidence provided in multiple studies, 7,9,14,17,21,22 the first DL algorithm for MSI prediction has received regulatory approval in Europe in 2022 ("MSIntuit CRC" by Owkin, France/ USA). However, various questions remain open, which is even more relevant now that this method can be used in routine diagnostics. The most important issue of existing MSI detection algorithms is their generalizability.²³ Usually, a pronounced performance drop is observed when deploying the trained models on external patient cohorts.²¹ Validation on external cohorts is crucial for testing the translation of models' prediction performance and hence generalization to independent datasets. The second issue is explainability, i.e., identifying which tissue patterns are associated with which genetic alterations. The third issue is the scope of the methods, i.e., their application to other biomarkers beyond MSI. Many genetic alterations are related to morphological features in tumor tissue. This is known for MSI²⁴ and BRAF mutations²⁵ in CRC and several mutations in other tumor types.^{26,27} However, few studies have investigated alterations beyond MSI in CRC in large patient cohorts. While recent studies investigating the DL-based prediction of MSI status included thousands of patients,¹⁷ studies investigating other biomarkers such as BRAF, KRAS, NRAS, and PIK3CA mutations are often limited to smaller cohorts with suboptimal data quality.28

From a technical point of view, the most widely used method for biomarker prediction in computational pathology is to train DL networks on image tiles obtained from histological wholeslide images (WSI).^{4,29} Mutation labels, however, only exist for the entire WSI, and it is unclear which regions on the WSI express morphologies that reflect underlying mutations. Therefore, tile predictions must be aggregated to slide predictions. A common approach is to apply transfer learning to models pre-trained on ImageNet and to use mean pooling for tile-to-slide aggregation.^{7,29-31} This method, the ImageNet pre-trained (INPT) approach, was first applied in histopathology by Coudray et al. in 2018.30 Recent proof-of-concept studies have suggested that the attention-based multiple-instance learning (attMIL)³² approach is superior to the INPT approach.¹² The image feature extractor (encoder) in attMIL can be pre-trained via self-supervised learning (SSL). Schirris et al. used SSLattMIL in a pilot study on a public dataset with 360 patients.¹² On this relatively small dataset, they reported a performance gain compared with the INPT approach. However, this performance gain has not been validated in larger cohorts. Similarly, other works have applied the attMIL approach with and without SSL to predict biomarkers but have only provided external validation in small datasets, if at all.^{5,33,34} In summary, previous evidence suggests that both SSL and attMIL are useful components in weakly supervised computational pathology pipelines, but this has not been systematically tested in a clinically relevant task with large-scale external validation. Such a lack of large-scale validation is a risk for the ultimate generalizability of any biomarker.^{23,35}

In this light, we aimed to fill two knowledge gaps by answering two questions: first, do attMIL and SSL really provide a performance gain compared with the INPT approach? Second, is MSI the only predictable biomarker in CRC, or is the mutational status of BRAF, KRAS, NRAS, and PIK3CA similarly predictable?

To this end, we implemented the INPT approach as a baseline and trained models for the prediction of multiple biomarkers in CRC. We tested the generalization on a test dataset and saw a performance drop, as expected. Subsequently, we implemented attMIL and applied it using two different SSL-trained feature extractors. We showed that one encoder outperformed the other by a large margin. The better encoder generalized well to the second dataset and consistently outperformed all other tested models. Finally, we extended attMIL by including clinical patient data and show that there was no synergy for the performance on the training dataset, although performance on the test dataset was increased.

RESULTS

attMIL outperforms the INPT approach for biomarker prediction

First, we investigated the predictability of MSI, BRAF, KRAS, NRAS, and PIK3CA directly from H&E histopathology images in the QUASAR cohort (Tables 1 and 2). We compared the INPT approach with SSL-attMIL using the SSL encoders by Ciga or Wang (Figures 1A-1C). We found that the best performances were obtained using image-only Wang-attMIL. For prediction of MSI, BRAF, KRAS, NRAS, and PIK3CA, areas under the receiver operating characteristic curve (AUROCs) of 0.94 \pm 0.02, 0.82 \pm 0.05, 0.67 \pm 0.04, 0.52 \pm 0.12, and 0.57 ± 0.07 were obtained, respectively (Figures 2A-2E). Previous studies have discussed that AUROCs of close to 0.9 with good generalization have a high discriminative power, which may be clinically relevant.9,29,36,37 In this sense, only MSI and BRAF mutation prediction reached a potentially clinically relevant level, but the prediction of the other investigated biomarkers did not.

Table 2. Clinico-pathologica	al features of both	cohorts
Patient/tumor characteristics	QUASAR	DACHS
Origin	United Kingdom	Germany
Number of patients	2,190	2,448
WSI format	SVS	SVS
MSI/dMMR ground truth	IHC 4-plex or IHC 2-plex	PCR 3-plex
MSI/dMMR, n (%)	246 (11%)	210 (9%)
MSS/pMMR, n (%)	1,529 (70%)	1,836 (75%)
Mean age at diagnosis (standard deviation)	62.20 (±9.60)	68.46 (±10.82)
Colon cancer, n (%)	1,474 (67%)	1,488 (61%)
Rectal cancer, n (%)	526 (24%)	960 (39%)
Organ unknown, n (%)	190 (9%)	0 (0%)
Female, n (%)	848 (39%)	1,012 (41%)
Male, n (%)	1,334 (61%)	1,436 (59%)
Gender unknown (%)	8 (0%)	0 (0%)
UICC stage I, n (%)	1 (0%)	485 (20%)
UICC stage II, n (%)	1,988 (91%)	801 (33%)
UICC stage III, n (%)	192 (9%)	822 (34%)
UICC stage IV, n (%)	0 (0%)	337 (14%)
UICC stage unknown (%)	9 (0%)	3 (0%)
BRAF mutation, n (%)	120 (5%)	151 (6%)
BRAF wild type, n (%)	1,358 (62%)	1,930 (79%)
BRAF status unknown (%)	712 (33%)	367 (15%)
KRAS mutation, n (%)	555 (25%)	667 (27%)
KRAS wild type, n (%)	882 (40%)	1,397 (57%)
KRAS status unknown (%)	753 (35%)	374 (15%)
NRAS mutation, n (%)	41 (2%)	n.a.
NRAS wild type, n (%)	1,430 (65%)	n.a.
NRAS status unknown (%)	719 (33%)	n.a.
PIK3CA mutation, n (%)	72 (3%)	n.a.
PIK3CA wild type, n (%)	1,343 (61%)	n.a.
PIK3CA status unknown (%)	775 (36%)	n.a.
Right-sided tumor, n (%)	754 (34%)	819 (33%)
Left-sided tumor, n (%)	1,158 (53%)	1,607 (66%)
Sidedness unknown, n (%)	150 (13%)	22 (1%)
Etiology	not specified	any
–	17 1 1 1 1 1	e

Details on missing image and/or biomarker data for patients in the QUASAR and DACHS cohort can be found in Figures S1 and S2, respectively.

Because using the AUROC as the sole metric is suboptimal,³⁸ we evaluated the model performance of the image-only WangattMIL model in Quasar at pre-defined threshold values (Figure 3). For MSI prediction, the 95% in-domain sensitivity threshold of value 0.21 yielded 236 true positive, 639 false positive, 9 false negative, and 890 true negative predictions across the five internal datasets. This globally corresponds to a sensitivity of 96.3%, a specificity of 58.2%, a positive predictive value (PPV) of 27%, and a negative predictive value (NPV) of 99%. At a threshold value of 0.5, *BRAF* status was globally predicted with a

Cell Reports Medicine Article

sensitivity of 73.3%, a specificity of 73.5%, a PPV of 19.7%, and an NPV of 96.9% across the five internal test sets. For *BRAF* status prediction notably, the requirement of 95% in-domain sensitivity comes at a high cost in specificity.

The INPT approach performed slightly but statistically significantly worse (p < 0.05, for MSI and *BRAF*) than the image-only Wang-attMIL model, achieving AUROCs of 0.90 \pm 0.04, 0.74 \pm 0.03, 0.63 \pm 0.06, 0.50 \pm 0.08, and 0.54 \pm 0.04 for MSI, *BRAF*, *KRAS*, *NRAS*, and *PIK3CA*, respectively. The Ciga-attMIL models yielded similar results as the INPT approach (AUROCs: MSI 0.90 \pm 0.03, *BRAF* 0.74 \pm 0.07, *KRAS* 0.59 \pm 0.03, *NRAS* 0.58 \pm 0.15, *PIK3CA* 0.57 \pm 0.15), where MSI-and *BRAF*-status prediction performances are compatible between the two approaches.

Together, these data show that the DL methods presented in this article have the potential to reach clinical-grade performance for the prediction of MSI, and near-clinical-grade performance for the prediction of *BRAF* but that they do not reach a high performance for *KRAS*, *NRAS*, and *PIK3CA*, despite using the best-performing image-only Wang-attMIL models in a large patient cohort.

There is no direct synergy between clinical data and image data in biomarker prediction

Further, we investigated whether or not adding baseline clinical data (gender, age, tumor location) as additional inputs improves the internal prediction performance of the best model. WangattMIL with clinical data (multi-input model) achieved the following AUROCs: MSI 0.94 \pm 0.02, BRAF 0.82 \pm 0.07 (Figures 2F and 2G), KRAS 0.66 ± 0.04, NRAS 0.49 ± 0.18, and PIK3CA 0.52 ± 0.17 (Table 1), yielding statistical compatibility with the image-only Wang-attMIL model for MSI and BRAF prediction. The solely clinical-data-based model achieved good prediction results as well (AUROCs: MSI 0.80 \pm 0.03, BRAF 0.77 \pm 0.08, Figures 2F and 2G; KRAS 0.50 \pm 0.06, NRAS 0.54 ± 0.13. PIK3CA 0.59 ± 0.06. Table 1). In particular. the solely clinical-data-based results for BRAF mutation prediction were close to those obtained with the image-only WangattMIL or the multi-input model and statistically compatible with all other DL approaches. This indicates that the visual features on H&E*stained tissue sections that are predictive of BRAF status are by themselves only slightly superior to the clinical variables. The same applies to the prediction of NRAS and PIK3CA mutation status. For KRAS and MSI status prediction, the image-based models outperformed the solely clinical-databased model. This indicates better predictability of biomarker status from image features than from clinical variables for these two biomarkers.

Image-only and multi-input attMIL generalizes better than the state of the art

Next, we assessed the generalizability of QUASAR-trained models on the DACHS cohort (Table 2; Figures S1 and S2). One set of tiles was color normalized using the Macenko method, while another set contained the same tiles without any color normalization. Here, we restricted the analysis to MSI and *BRAF* biomarker prediction, as other biomarkers had already been shown to perform poorly during internal validation.

preprocessing

image

tiles

Article

Α

В


MS

BRAF

РІКЗСА

KRAS

NRAS



Methods Comparision

Coudray

SSL-

attMIL

clinical data

only

C

Ciga-attMIL

Wang-attMIL

multi-input

(Wang-attMIL +

clinical data)

Attention-Based Multiple Instance Learning Pipeline

DACHS

N=2448

MSI

BRAF

rojection

256

С

biomarker

prediction

via

extraci

224x224x3

4x774x3

optional: concatenate clinical features

external

Cohorts and Experimental Layout

Ε

validation

cross-

validation

Figure 1. Schematic workflow of this study


(A) Schematic summary of attMIL and the multi-input DL architecture: a WSI is tessellated into smaller tiles, that are subsequently pre-processed and passed through the encoder to give image feature vectors. In the multi-input case, each image feature vector is concatenated by a vector representing the patient's clinical data. The set of image feature vectors per WSI is then used as input to the attMIL model. In a first embedding block, the attMIL model reduces the dimension of each tile's initial feature vector to 256 (from 2,048 [+4 if clinical data are used in the input] when using the Wang encoder). Then, the attention score per tile is calculated. Using the attention score, the attention-weighted sum over all embedded feature vectors can be evaluated to give a 256-dimensional vector representing the entire WSI (green). Finally, this vector is passed through a classification block to obtain a biomarker prediction for the input WSI. (B) Targets and cohorts used in internal and external validation. For internal validation, we tested for MSI, BRAF, PIK3CA, KRAS, and NRAS status. Externally only

for MSI and BRAF status.

(C) List of all six DL approaches that were compared in this study. E, encoder network; P, embedding block that embeds feature vectors into a lower dimensional space; A, attention layers; Π, attention weighting; Σ, sum; C, classification block.

The image-only Wang-attMIL models and the multi-input models yielded a high performance for the prediction of MSI and BRAF status (Figures 2F and 2G). For MSI and BRAF prediction on color-normalized tiles in the external validation cohort, AUROCs of 0.92 \pm 0.01 and 0.81 \pm 0.01 and 0.92 \pm 0.01 and 0.85 ± 0.01 were obtained by image-only WangattMIL and multi-input, respectively (Figures 2F-2I). For BRAF mutation prediction, this shows a better generalization of the multi-input compared with the image-only Wang-attMIL models. These high AUROCs correspond to high areas under the precision-recall curve (AUPRCs) (Table 1; Figure S3), pointing to potential clinical applicability. For MSI prediction in DACHS with the 95% in-domain sensitivity threshold value of 0.21, the averaged models' scores achieved a sensitivity of 90.5%, a specificity of 79.6%, a PPV of 33.7%, and an NPV of 98.6%. At a threshold value of 0.5, BRAF status was predicted with a sensitivity of 73.3%, a specificity of 73.5%, a PPV of 19.7%, and an NPV of 96.9% (Figure 3). Clinical statistics for correctly classified and misclassified patients in QUASAR and DACHS at a threshold value of 0.5 are given in Tables S1 and S2. The models had difficulties in correctly predicting MSI-positive patients with rectal cancer in the DACHS cohort. In the case of rectal carcinomas, the odds ratio for the correct classification of an MSI-positive patient in QUASAR compared with DACHS was 11.7, suggesting that more data from patients with rectal carcinoma are required in future datasets.

Notably, when using the Wang encoder, the performance in the validation cohort was not dependent on the presence of color





(A-E) Cross-validated AUROCs for all biomarkers obtained using the Wang-attMIL model.

(F and G) Internal cross-validated performance of all models on QUASAR and external validation on DACHS (with and without Macenko color normalization). The bar charts show the distribution of five technical replicates and error bars indicate 95% confidence intervalls. In internal cross-validation, replicates are separate cross-validation runs. In external validation, replicates are deployments of the individual cross-validation models. Central markers give the average AUROC score in each setup.

(H and I) The error bars indicate 95% confidence intervals AUROCs obtained by models trained in each of the five folds for MSI and *BRAF* status prediction, applied to the external validation set QUASAR.

CellPress

Article






Figure 3. Test statistics for a potential screening tool using the Wang-attMIL image-only models

Test performances at thresholds of 0.25, 0.5, and 0.75 (top) and at a threshold that yielded 95% in-domain sensitivity (95-Sens. threshold) averaged across the five models per biomarker. In-domain performances are measured by the summed model predictions over respective test sets. External performances on DACHS are obtained by averaging scores for biomarker prediction over all five Wang-attMIL models per biomarker. Clinical statistics for correctly classified and misclassified patients in QUASAR and DACHS at a threshold value of 0.5 are given in Tables S7 and S8.

normalization—we observed an equivalent performance on noncolor-normalized tiles (image-only Wang-attMIL: MSI 0.91 \pm 0.01, *BRAF* 0.78 \pm 0.03; multi-input: MSI 0.92 \pm 0.01, 0.84 \pm 0.02). Here the multi-input outperformed the image-only Wang-attMIL models for both MSI and *BRAF* status prediction. This provides further evidence that (1) the image-only WangattMIL models generalize very well and do not suffer from domain shifts and that (2) addition of clinical data can improve generalization even further. Thus, combining morphological features with the patient's age, gender, and tumor location can improve performance.

In contrast, the INPT models trained on QUASAR showed a marked performance drop on color-normalized DACHS images (AUROCs: MSI 0.86 \pm 0.02, *BRAF* 0.78 \pm 0.02) and further dropped in performance for the non-normalized images (AUROCs: MSI 0.80 \pm 0.04, *BRAF* 0.75 \pm 0.03). This shows that the INPT approach is less stable and generalizes less well than the image-only Wang-attMIL or multi-input models. The robustness of the Wang-attMIL approach seemed to be due to the particular encoder since the Ciga-attMIL model generalized poorly (AUROCs color normalized: MSI 0.72 \pm 0.03, *BRAF* 0.73 \pm 0.02; AUROCs non-normalized: MSI 0.71 \pm 0.05, *BRAF* 0.68 \pm 0.06; Table 1). Results for the analysis of variances (ANOVA) for AUROCs obtained with trained models in internal validation and in external validation on DACHS for MSI and *BRAF* status prediction are listed in Tables S3–S8.

SSL-attMIL is domain-shift invariant

Domain shifts can still hide behind high AUROC values and can severely limit the real-world performance of DL models.³⁸ We investigated the distribution of the image-only Wang-attMIL model prediction scores for MSI and *BRAF* in the training and test cohort. We found that the prediction scores were similarly distributed in the training and test set for the image-only Wang-attMIL (Figure S4) as well as for the multi-input models (Figure S5). In summary, these data show that Wang-attMIL yields classifiers with high generalizability

across the two datasets, which are independent of Macenko normalization and do not display domain shifts. Furthermore, adding clinical data to the models leads to even better generalization.

Attention-based models attend to relevant tissue regions

To comprehend the decision-making processes of trained DL models, we investigated the visual patterns in their spatial context on WSIs. We separately visualized attention and prediction heatmaps for typical patients for the image-only Wang-attMIL models (Figures 4A and 4B). For MSI prediction, high-attention regions were confined to the tumor tissue, while fibromuscular tissue and non-tumor epithelium were not attended to as much by the model (Figures 4A and 4B). In BRAF prediction, however, the attention was more spread out. Tumor tissue is still attended more to than non-tumor tissue but to a lesser extent (Figures 4A and 4B). This indicates that either the BRAF prediction model did not learn to focus sufficiently on the tumor tissue or that the BRAF prediction model learned that visual features outside of the tumor region are somewhat relevant to making predictions. In particular, lymphocyte-infiltrated muscle tissue was assigned a high BRAF and attention score. Confounding factors in images for BRAF status prediction are yet another possibility. Further high-resolution heatmaps for MSI and BRAF status for typical patients are available at Zenodo: https://doi.org/10.5281/zenodo.7454743. Interestingly, the presence of pen marks on some slides did not confuse the models, as pen marks were assigned a very low attention score, showing that the image-only Wang-attMIL model is very robust, even to the presence of artifacts.

Distinct visual features drive MSI and BRAF prediction

MSI and *BRAF* mutant status are highly correlated; therefore, we addressed whether the models recognize different sets of visual features for either target. First, we investigated whether *BRAF* mutations can be predicted in the MSI and microsatellite stable






Figure 4. Spatial patterns of attention and classification of MSI and *BRAF* prediction models

(A and B) MSI score (A) and *BRAF* score (B) with corresponding attention maps for a typical MSI- and *BRAF*-positive patient from the DACHS cohort.

(C) Plain slide view. Scores were obtained with the best in-domain models trained on QUASAR (Wang-attMIL model). The displayed attention distribution is the normalized attention $\hat{a} = \frac{a - a_{min}}{a_{max}}$, where *a* is the attention score and a_{min} and a_{max} are the minimum and maximum scores on the WSI. This attention map highlights "relevant" tumor regions, irrespective of whether they were predicted to be MSI or MSS. The classification scores of the model show the "MSI-ness" and "*BRAF*-ness" for each tile. In both cases, the model correctly predicted MSI and BRAF status on the patient level.



Article




Figure 5. Biomarker predictability in patient subgroups and explainability

(A) Internal validation ROCs for BRAF mutation prediction in the subgroup of MSI patients.

(B) Internal validation ROCs for BRAF status prediction in the subgroup of MSS patients.

(C) Internal validation ROCs for MSI/MSS status prediction in the subgroup of BRAF-mutated patients.

(D) Internal validation ROCs for MSI/MSS status prediction in the subgroup of BRAF wild-type patients.

(legend continued on next page)



(MSS) subgroups of the QUASAR trial dataset. Using image-only Wang-attMIL models, the DL system was able to detect BRAF mutational status in the MSI subgroup, reaching a cross-validated AUROC of 0.73 ± 0.06 (Figure 5A). However, BRAF status was not predictable in the MSS subgroup, reaching an AUROC of 0.66 ± 0.10 (Figure 5B). Second, we repeated the analysis for MSI status prediction in BRAF-mutated and wild-type subgroups in analogy: MSI status was predictable in BRAF^{wt} patients (AUROC 0.89 \pm 0.06, Figure 5C) and BRAF^{mut} patients (AUROC 0.78 ± 0.15, Figure 5D). We further investigated the visual features present in image tiles that were assigned high attention and a high-class prediction score at the same time. We found that MSI (Figure 5E) and MSS (Figure 5F) tiles showed similar patterns to those described previously: poorly differentiated tumor glands with immune-infiltrated stroma in MSI versus well-differentiated stroma-rich tissue areas for MSS.^{17,24} BRAF^{mut} (Figure 5G) and BRAF^{wt} (Figure 5H) top tiles showed different prominent patterns than MSI and MSS tiles, with mucinous differentiation dominating BRAF^{mut} tiles and welldifferentiated, stroma-rich patterns dominating BRAF^{wt} tiles. Using gradient-weighted class activation mapping (Grad-CAM) to highlight relevant subregions in these top tiles, we found that the models indeed focused on these tissue structures (Figures 5E–5H). MSI and BRAF prediction scores were correlated in all patient subgroups (Figure S6). Taken together, these data show that MSI and BRAF prediction models detect distinct visual features that are compatible with previous knowledge; however, MSI features appear to be more distinct, as MSI status is easier detectable in subgroups of BRAF^{mut}/BRAF^{wt} than BRAF status in subgroups of MSI/MSS.

DISCUSSION

MSI prediction from histopathology with DL has been investigated since 2019.7,14,17,22 Earlier works used the INPT approach using mean pooling for slide-level aggregation.⁷ Recent studies have investigated attention-based MIL approaches in the hope of less noisy supervision and creating models able to learn to combine global features.39-42 Most recently, SSL methods have been adopted in the histopathology domain.¹² In a smaller pilot study, the attMIL approach has shown superior performance compared with the INPT approach.¹² The main limitations of many of these works, however, are that (1) they focus on only a few clinically relevant tasks and (2) they are not validated on external cohorts, thus lacking performance evaluation in realistic scenarios. First, we tested the performance of two attMILmodels with different pre-trained encoders on multiple clinically relevant biomarkers. Second, we investigated their external validation performance on a large dataset for internally well-predictable biomarkers. For the attMIL approach, this degree of

Cell Reports Medicine Article

large-scale validation is required for clinical translation but was missing from previous studies.²³

This study evaluates current state-of-the-art methods for biomarker prediction in CRC from pathology slides in a realistic evaluation setting: SSL-attMIL with the Wang encoder outperformed all other approaches. This confirms the superiority of the attMIL approach when combined with an appropriate encoder on a large external dataset. Our Wang-attMIL models were generalizable and invariant to the color normalization in the test set. In contrast, this was not the case for our CigaattMIL models, where the encoder was trained on a similar, but much smaller, dataset compared with the Wang encoder. This provides empirical evidence that Wang's encoder trained via the clustering-guided contrastive learning (CCL) algorithm is superior to Ciga's encoder trained via SimCLR for the biomarker prediction investigated in this article. Thus, the Wang encoder provides an ideal backbone for the attMIL approach for biomarker prediction at hand. Using the image-only WangattMIL models, our approach improves the AUROC for MSI prediction from 0.68 to 0.92 for training on QUASAR and testing on DACHS compared with Echle et al.⁹ These results are in line with previous studies, which demonstrated the superiority of the att-MIL approach for biomarker prediction.^{12,22,40,43}

Further, we demonstrated that morphological features most relevant for a prediction made by our best image-only MSI and *BRAF* models are in line with previous findings and pathological knowledge.^{17,24,25} In addition, the current study extends these previous findings by (1) showing the superiority of the Wang-attMIL models using large cohorts with thousands of patients and (2) investigating multiple biomarkers beyond MSI.

Finally, we tested extensions of the image-only Wang-attMIL model by concatenating image vectors with vectors representing clinical patient data. Here, we did not see direct synergy in performance on the QUASAR cohort, but we did see enhanced prediction performance for patients in the DACHS cohort. This is true in particular for the prediction of *BRAF* biomarker status, which shows a weaker morphological phenotype compared with MSI mutations. In this case, multi-input models stabilized predictions across different datasets.

Prediction of genetic alterations such as MSI and *BRAF* mutation is regarded as one of the most relevant applications of computational pathology.² Exceeding pure research applications, the prediction of MSI status has enormous commercial potential. This is evident in multiple companies that have developed solutions for MSI status prediction,^{43–45} one of which has received CE/IVD regulatory approval in Europe in 2022 ("MSIntuit CRC" by Owkin). Here, we chose to make our technology publicly available under an MIT open-source license so that anyone can re-use it.

⁽E and F) Top scoring tiles and Grad-CAM saliency maps for MSI (E) and MSS (F) status for the best in-domain Wang+attMIL model deployed on the DACHS cohort.

⁽G and H) Top scoring tiles for *BRAF*-mutated (G) and *BRAF* wild-type (H) status for the best in-domain Wang+attMIL model deployed on the DACHS cohort. For better interpretability, six out-of-focus tiles are not shown in this panel.

In (E)–(G), top tiles are the highest, top 5%, and top 10% scoring tiles in terms of the product of the tile's attention and the tile's classification score (left to right) for the patients with the highest overall classification score for the target mutation (top to bottom). High-resolution images can be found at Zenodo: https://doi.org/10.5281/zenodo.7454743. Correlation of prediction scores for MSI and *BRAF* status for the best image-only model can be found in Figure S6.



However, we also identified limitations of DL-based biomarker prediction. While previous studies have suggested that mutations in *KRAS*, *NRAS*, and *PIK3CA* might be predictable from pathology images,^{4,22,46} we show that this performance is not in a clinically relevant range with the methods described in this article. Although prediction of these biomarkers was possible with non-random AUROCs above 0.5, this is far from suitable for clinical application. Also, we show that a trivial model that uses only age, gender, organ, and sidedness as an input reaches similar performances for the prediction of *NRAS* and *PIK3CA* genes (Table 1). Thereby, our study provides suggestive evidence that despite the use of large, multi-centric patient cohorts and powerful DL models, it is not possible to predict the mutational status of *KRAS*, *NRAS*, and *PIK3CA* from CRC histopathology slides with current methods.

STAR***METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Ethics statement
 - O Patient cohorts
- METHOD DETAILS
 - Image preprocessing
 - O Biomarker prediction from whole slide images
 - Visualization and explainability
 - Implementation of the INPT approach
 - Implementation of attention-based multiple instance learning
 - Implementation of multi-input prediction models
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - Experimental design and statistics

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j. xcrm.2023.100980.

ACKNOWLEDGMENTS

The authors are grateful for support from the tissue bank of the National Center for Tumor Diseases (NCT) at the Institute of Pathology at University Hospital Heidelberg, Heidelberg, Germany, for providing access to the biobank data. J.N.K. is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111), the Max-Eder-Programme of the German Cancer Aid (grant #70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C), and the German Academic Exchange Service (SECAI, 57616814). The DACHS study (H.B. and M.H.) was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HO 5117/2-2, HE 5998/2-1, HE 5998/2-2, KL 2354/3-1, KL 2354/3-2, RO 2270/8-1, RO 2270/8-2, BR 1704/17-1, and BR 1704/17-2), the Interdisciplinary Research Program of the NCT (Germany), and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815,



01ER1505A, and 01ER1505B). P.Q. and N.P.W. are supported by Yorkshire Cancer Research Program grants L386 (QUASAR series) and L394 (YCR BCIP series).

AUTHOR CONTRIBUTIONS

J.M.N. performed the initial analysis and wrote the initial version of the manuscript. J.N.K., Y.S., G.P.V., and M.v.T. contributed to the analyses. The software was mainly developed by M.v.T. with contributions from J.F., A.B., W.U., J.M.N., P.Q., N.P.W., H.I.G., G.G.A.H., S.D.R., H.B., A.B., and M.H. contributed materials and clinical expertise. All authors contributed to the experimental design, the interpretation of the results, and the writing of the final manuscript and agreed to the submission of this paper.

DECLARATION OF INTERESTS

For transparency, we provide the following information: J.N.K. declares consulting services for Owkin, France; Panakeia, UK; and DoMore Diagnostics, Norway. P.Q. and N.P.W. declare research funding from Roche and PQ consulting and speaker services for Roche. P.Q. is a National Institute of Health Research senior investigator.

Received: September 25, 2022 Revised: December 28, 2022 Accepted: February 24, 2023 Published: March 22, 2023

REFERENCES

- Esteva, A., Kuprel, B., Novoa, R.A., Ko, J., Swetter, S.M., Blau, H.M., and Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature 542, 115–118.
- Heinz, C.N., Echle, A., Foersch, S., Bychkov, A., and Kather, J.N. (2022). The future of artificial intelligence in digital pathology - results of a survey across stakeholder groups. Histopathology 80, 1121–1127.
- Echle, A., Rindtorff, N.T., Brinker, T.J., Luedde, T., Pearson, A.T., and Kather, J.N. (2021). Deep learning in cancer pathology: a new generation of clinical biomarkers. Br. J. Cancer *124*, 686–696. https://doi.org/10. 1038/s41416-020-01122-x.
- Cifci, D., Foersch, S., and Kather, J.N. (2022). Artificial intelligence to identify genetic alterations in conventional histopathology. J. Pathol. 257, 430–444. https://doi.org/10.1002/path.5898.
- Chen, R.J., Lu, M.Y., Williamson, D.F.K., Chen, T.Y., Lipkova, J., Noor, Z., Shaban, M., Shady, M., Williams, M., Joo, B., and Mahmood, F. (2022). Pan-cancer integrative histology-genomic analysis via multimodal deep learning. Cancer Cell 40, 865–878.e6.
- Bera, K., Schalper, K.A., Rimm, D.L., Velcheti, V., and Madabhushi, A. (2019). Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat. Rev. Clin. Oncol. 16, 703–715.
- Kather, J.N., Pearson, A.T., Halama, N., Jäger, D., Krause, J., Loosen, S.H., Marx, A., Boor, P., Tacke, F., Neumann, U.P., et al. (2019). Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat. Med. 25, 1054–1056.
- Cao, R., Yang, F., Ma, S.-C., Liu, L., Zhao, Y., Li, Y., Wu, D.-H., Wang, T., Lu, W.-J., Cai, W.-J., et al. (2020). Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics 10, 11080–11091.
- Echle, A., Grabsch, H.I., Quirke, P., van den Brandt, P.A., West, N.P., Hutchins, G.G.A., Heij, L.R., Tan, X., Richman, S.D., Krause, J., et al. (2020). Clinical-grade detection of microsatellite instability in colorectal tumors by deep learning. Gastroenterology *159*, 1406–1416.e11.
- Bilal, M., Ahmed Raza, S.E., Azam, A., Graham, S., Ilyas, M., Cree, I.A., Snead, D., Minhas, F., and Rajpoot, N.M. (2021). Novel Deep Learning Algorithm Predicts the Status of Molecular Pathways and Key Mutations in



Colorectal Cancer from Routine Histology Images. https://doi.org/10. 1101/2021.01.19.21250122.

- Lee, S.H., Song, I.H., and Jang, H.-J. (2021). Feasibility of deep learningbased fully automated classification of microsatellite instability in tissue slides of colorectal cancer. Int. J. Cancer 149, 728–740.
- Schirris, Y., Gavves, E., Nederlof, I., Horlings, H.M., and Teuwen, J. (2022). DeepSMILE: contrastive self-supervised pre-training benefits MSI and HRD classification directly from H&E whole-slide images in colorectal and breast cancer. Med. Image Anal. 79, 102464. https://doi.org/10. 1016/j.media.2022.102464.
- Schrammen, P.L., Ghaffari Laleh, N., Echle, A., Truhn, D., Schulz, V., Brinker, T.J., Brenner, H., Chang-Claude, J., Alwers, E., Brobeil, A., et al. (2022). Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. J. Pathol. 256, 50–60.
- 14. Yamashita, R., Long, J., Longacre, T., Peng, L., Berry, G., Martin, B., Higgins, J., Rubin, D.L., and Shen, J. (2021). Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. Lancet Oncol. 22, 132–141.
- Jang, H.-J., Lee, A., Kang, J., Song, I.H., and Lee, S.H. (2020). Prediction of clinically actionable genetic alterations from colorectal cancer histopathology images using deep learning. World J. Gastroenterol. 26, 6207–6223.
- Kather, J.N., and Calderaro, J. (2020). Development of AI-based pathology biomarkers in gastrointestinal and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 591–592.
- Echle, A., Laleh, N.G., Schrammen, P.L., West, N.P., Trautwein, C., Brinker, T.J., Gruber, S.B., Buelow, R.D., Boor, P., Grabsch, H.I., et al. (2021). Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: a systematic literature review. ImmunoInformatics 3-4, 100008.
- Mlecnik, B., Bindea, G., Angell, H.K., Maby, P., Angelova, M., Tougeron, D., Church, S.E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016). Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698–711.
- Yoon, H.H., Jin, Z., Kour, O., Kankeu Fonkoua, L.A., Shitara, K., Gibson, M.K., Prokop, L.J., Moehler, M., Kang, Y.-K., Shi, Q., and Ajani, J.A. (2022). Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. *8*, 1456–1465. https://doi.org/10.1001/jamaoncol. 2022.3707.
- Poston, G.J., Tait, D., O'Connell, S., Bennett, A., and Berendse, S.; Guideline Development Group (2011). Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343, d6751.
- Echle, A., Ghaffari Laleh, N., Quirke, P., Grabsch, H.I., Muti, H.S., Saldanha, O.L., Brockmoeller, S.F., van den Brandt, P.A., Hutchins, G.G.A., Richman, S.D., et al. (2022). Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a prescreening tool for clinical application. ESMO Open 7, 100400.
- 22. Bilal, M., Raza, S.E.A., Azam, A., Graham, S., Ilyas, M., Cree, I.A., Snead, D., Minhas, F., and Rajpoot, N.M. (2021). Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study. Lancet. Digit. Health 3, e763–e772.
- Kleppe, A., Skrede, O.-J., De Raedt, S., Liestøl, K., Kerr, D.J., and Danielsen, H.E. (2021). Designing deep learning studies in cancer diagnostics. Nat. Rev. Cancer 21, 199–211.
- 24. Greenson, J.K., Huang, S.-C., Herron, C., Moreno, V., Bonner, J.D., Tomsho, L.P., Ben-Izhak, O., Cohen, H.I., Trougouboff, P., Bejhar, J., et al. (2009). Pathologic predictors of microsatellite instability in colorectal cancer. Am. J. Surg. Pathol. 33, 126–133.

- Pai, R.K., Jayachandran, P., Koong, A.C., Chang, D.T., Kwok, S., Ma, L., Arber, D.A., Balise, R.R., Tubbs, R.R., Shadrach, B., and Pai, R.K. (2012). BRAF-Mutated, microsatellite-stable adenocarcinoma of the proximal colon. Am. J. Surg. Pathol. *36*, 744–752. https://doi.org/10.1097/pas. 0b013e31824430d7.
- Rosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D.C., Moser, A.R., MacLeod, C.L., Shyamala, G., Gillgrass, A.E., and Cardiff, R.D. (2002). Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am. J. Pathol. *161*, 1087–1097.
- 27. Hewitt, L.C., Saito, Y., Wang, T., Matsuda, Y., Oosting, J., Silva, A.N.S., Slaney, H.L., Melotte, V., Hutchins, G., Tan, P., et al. (2019). KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. Gastric Cancer 22, 1193–1203.
- 28. Howard, F.M., Dolezal, J., Kochanny, S., Schulte, J., Chen, H., Heij, L., Huo, D., Nanda, R., Olopade, O.I., Kather, J.N., et al. (2021). The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat. Commun. 12, 4423.
- Shmatko, A., Ghaffari Laleh, N., Gerstung, M., and Kather, J.N. (2022). Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat. Cancer 3, 1026–1038.
- Coudray, N., Ocampo, P.S., Sakellaropoulos, T., Narula, N., Snuderl, M., Fenyö, D., Moreira, A.L., Razavian, N., and Tsirigos, A. (2018). Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat. Med. 24, 1559–1567.
- Fu, Y., Jung, A.W., Torne, R.V., Gonzalez, S., Vöhringer, H., Shmatko, A., Yates, L.R., Jimenez-Linan, M., Moore, L., and Gerstung, M. (2020). Pancancer computational histopathology reveals mutations, tumor composition and prognosis. Nat. Cancer 1, 800–810.
- Ilse, M., Tomczak, J.M., and Welling, M. (2018). Attention-based deep multiple instance learning. Preprint at arXiv. https://doi.org/10.48550/ar-Xiv.1802.04712.
- Saldanha, O.L., Loeffler, C.M.L., Niehues, J.M., van Treeck, M., Seraphin, T.P., Hewitt, K.J., Cifci, D., Veldhuizen, G.P., Ramesh, S., Pearson, A.T., et al. (2022). Self-supervised deep learning for pan-cancer mutation prediction from histopathology. Preprint at bioRxiv. https://doi.org/10.1101/ 2022.09.15.507455.
- Seraphin, T.P., Luedde, M., Roderburg, C., van Treeck, M., Schneider, P., Buelow, R.D., Boor, P., Loosen, S., Provaznik, Z., Mendelsohn, D., et al. (2022). Prediction of heart transplant rejection from routine pathology slides with self-supervised Deep Learning. Preprint at medRxiv. https:// doi.org/10.1101/2022.09.29.22279995.
- Howard, F.M., Kather, J.N., and Pearson, A.T. (2023). Multimodal deep learning: an improvement in prognostication or a reflection of batch effect? Cancer Cell 41, 5–6. https://doi.org/10.1016/j.ccell.2022.10.025.
- Mandrekar, J.N. (2010). Receiver operating characteristic curve in diagnostic test assessment. J. Thorac. Oncol. 5, 1315–1316.
- 37. Campanella, G., Hanna, M.G., Geneslaw, L., Miraflor, A., Werneck Krauss Silva, V., Busam, K.J., Brogi, E., Reuter, V.E., Klimstra, D.S., and Fuchs, T.J. (2019). Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat. Med. 25, 1301–1309.
- Kleppe, A. (2022). Area under the curve may hide poor generalisation to external datasets. ESMO Open 7, 100429.
- Zeng, Q., Klein, C., Caruso, S., Maille, P., Laleh, N.G., Sommacale, D., Laurent, A., Amaddeo, G., Gentien, D., Rapinat, A., et al. (2022). Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J. Hepatol. 77, 116–127. https://doi.org/10.1016/j.jhep.2022.01.018.
- 40. Ghaffari Laleh, N., Muti, H.S., Loeffler, C.M.L., Echle, A., Saldanha, O.L., Mahmood, F., Lu, M.Y., Trautwein, C., Langer, R., Dislich, B., et al. (2022). Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Med. Image Anal. 79, 102474.



- 41. Lipkova, J., Chen, T.Y., Lu, M.Y., Chen, R.J., Shady, M., Williams, M., Wang, J., Noor, Z., Mitchell, R.N., Turan, M., et al. (2022). Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies. Nat. Med. 28, 575-582.
- 42. Lu, M.Y., Chen, T.Y., Williamson, D.F.K., Zhao, M., Shady, M., Lipkova, J., and Mahmood, F. (2021). Al-based pathology predicts origins for cancers of unknown primary. Nature 594, 106-110.
- 43. Saillard, C., Dehaene, O., Marchand, T., Moindrot, O., Kamoun, A., Schmauch, B., and Jegou, S. (2021). Self supervised learning improves dMMR/MSI detection from histology slides across multiple cancers. Preprint at arXiv. https://doi.org/10.48550/arXiv.2109.05819.
- 44. Joshi, R.P., Kruger, A.J., Sha, L., Kannan, M., Khan, A.A., and Stumpe, M. (2020). Learning relevant H&E slide morphologies for prediction of colorectal cancer tumor mutation burden using weakly supervised deep learning. J. Clin. Orthod. 38, e15244.
- 45. Arslan, S., Mehrotra, D., Schmidt, J., Geraldes, A., Singhal, S., Hense, J., Li, X., Bass, C., Kather, J.N., and Raharja-Liu, P. (2022). Deep learning can predict multi-omic biomarkers from routine pathology images: a systematic large-scale study. Preprint at bioRxiv. https://doi.org/10.1101/2022. 01.21.477189.
- 46. Kather, J.N., Heij, L.R., Grabsch, H.I., Loeffler, C., Echle, A., Muti, H.S., Krause, J., Niehues, J.M., Sommer, K.A.J., Bankhead, P., et al. (2020). Pan-cancer image-based detection of clinically actionable genetic alterations. Nat. Cancer 1, 789-799.
- 47. Quasar Collaborative Group; Gray, R., Barnwell, J., McConkey, C., Hills, R.K., Williams, N.S., and Kerr, D.J. (2007). Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 2020-2029
- 48. Brenner, H., Chang-Claude, J., Seiler, C.M., Stürmer, T., and Hoffmeister, M. (2006). Does a negative screening colonoscopy ever need to be repeated? Gut 55, 1145-1150.
- 49. Quirke, P., and Morris, E. (2007). Reporting colorectal cancer. Histopatholoav 50. 103-112.
- 50. Brenner, H., Chang-Claude, J., Seiler, C.M., and Hoffmeister, M. (2011). Long-term risk of colorectal cancer after negative colonoscopy. J. Clin. Oncol. 29, 3761-3767.
- 51. Hoffmeister, M., Jansen, L., Rudolph, A., Toth, C., Kloor, M., Roth, W., Bläker, H., Chang-Claude, J., and Brenner, H. (2015). Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J. Natl. Cancer Inst. 107, djv045.
- 52. Hutchins, G., Southward, K., Handley, K., Magill, L., Beaumont, C., Stahlschmidt, J., Richman, S., Chambers, P., Seymour, M., Kerr, D., et al. (2011). Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270.
- 53. Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., Meltzer, S.J., Rodriguez-Bigas, M.A., Fodde, R., Ranzani, G.N., and Srivastava, S. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257.
- 54. Findeisen, P., Kloor, M., Merx, S., Sutter, C., Woerner, S.M., Dostmann, N., Benner, A., Dondog, B., Pawlita, M., Dippold, W., et al. (2005). T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Bes 65 8072-8078

55. Bläker, H., Helmchen, B., Bönisch, A., Aulmann, S., Penzel, R., Otto, H.F., and Rieker, R.J. (2004). Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand. J. Gastroenterol. 39, 748-753.

CellPress

- 56. Jia, M., Jansen, L., Walter, V., Tagscherer, K., Roth, W., Herpel, E., Kloor, M., Bläker, H., Chang-Claude, J., Brenner, H., and Hoffmeister, M. (2016). No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. Br. J. Cancer 115, 1359-1366.
- 57. Muti, H.S., Loeffler, C., Echle, A., Heij, L.R., Buelow, R.D., Krause, J., Broderius, L., Niehues, J., Liapi, G., Boor, P., et al. (2020). The Aachen Protocol for Deep Learning Histopathology: A Hands-On Guide for Data Preprocessing. https://doi.org/10.5281/zenodo.3694994.
- 58. Pech-Pacheco, J.L., Cristobal, G., Chamorro-Martinez, J., and Fernandez-Valdivia, J. (2000). Diatom autofocusing in brightfield microscopy: a comparative study. In Proceedings 15th International Conference on Pattern Recognition. ICPR-2000, pp. 314-317.
- 59. Macenko, M., Niethammer, M., Marron, J.S., Borland, D., Woosley, J.T., Guan, X., Schmitt, C., and Thomas, N.E. (2009). A method for normalizing histology slides for quantitative analysis. In 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro, pp. 1107-1110.
- 60. Chen, T., Kornblith, S., Norouzi, M., and Hinton, G. (2020). A Simple framework for contrastive learning of visual representations. Preprint at arXiv. https://doi.org/10.48550/arXiv.2002.05709.
- 61. Ciga, O., Xu, T., and Martel, A.L. (2022). Self supervised contrastive learning for digital histopathology. Mach. Learn. Appl. 7, 100198.
- 62. Wang, X., Du, Y., Yang, S., Zhang, J., Wang, M., Zhang, J., Yang, W., Huang, J., and Han, X. (2023). RetCCL: clustering-guided contrastive learning for whole-slide image retrieval. Med. Image Anal. 83, 102645.
- 63. Brockmoeller, S., Echle, A., Ghaffari Laleh, N., Eiholm, S., Malmstrøm, M.L., Plato Kuhlmann, T., Levic, K., Grabsch, H.I., West, N.P., Saldanha, O.L., et al. (2022). Deep Learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. J. Pathol. 256, 269-281. https://doi.org/10.1002/path.5831.
- 64. Selvaraju, R.R., Cogswell, M., Das, A., Vedantam, R., Parikh, D., and Batra, D. (2017). Grad-cam: visual explanations from deep networks via gradient-based localization. Proc. Est. Acad. Sci. Biol. Ecol.
- 65. Zhou, B., Khosla, A., Lapedriza, A., Oliva, A., and Torralba, A. (2016). Lapedriza Learning deep features for discriminative localization. Proc. Est. Acad, Sci, Biol, Ecol,
- 66. van Treeck, M., Cifci, D., Laleh, N.G., Saldanha, O.L., Loeffler, C.M.L., Hewitt, K.J., Muti, H.S., Echle, A., Seibel, T., Seraphin, T.P., et al. (2021). DeepMed: a unified, modular pipeline for end-to-end deep learning in computational pathology. Preprint at bioRxiv. https://doi.org/10.1101/ 2021.12.19.473344.
- 67. Kingma, D.P., and Ba, J. (2014). Adam: a method for stochastic optimization. Preprint at arXiv. https://doi.org/10.48550/arXiv.1412.6980.
- 68. Smith, L.N., and Topin, N. (2017). Super-convergence: very fast training of neural networks using large learning rates. Preprint at arXiv. https://doi. org/10.48550/arXiv.1708.07120.
- 69. Howard, J., and Gugger, S. (2020). Fastai: a layered API for deep learning. Information 11, 108.
- 70. Howard, J., and Gugger, S. (2020). Deep Learning for Coders with Fastai and PyTorch ("O'Reilly Media, Inc.").



STAR***METHODS**

KEY RESOURCES TABLE

Nvidia Corp., Santa Clara, California.	N/A
GitHub: https://github.com/KatherLab/crc-models-2022	this manuscript
Zenodo: https://doi.org/10.5281/zenodo.7454743	https://doi.org/10.5281/zenodo.7454743
GitHub: https://github.com/ozanciga/self-supervised- histopathology	https://doi.org/10.1016/j.mlwa.2021.100198
GitHub: https://github.com/Xiyue-Wang/RetCCL	https://doi.org/10.1016/j.media.2022.102645
GitHub: https://github.com/KatherLab/marugoto	N/A
GitHub: https://github.com/KatherLab/deepmed	N/A
SOURCE	IDENTIFIER
	GitHub: https://github.com/KatherLab/deepmed GitHub: https://github.com/KatherLab/marugoto GitHub: https://github.com/Xiyue-Wang/RetCCL GitHub: https://github.com/ozanciga/self-supervised- histopathology Zenodo: https://doi.org/10.5281/zenodo.7454743 GitHub: https://github.com/KatherLab/crc-models-2022

RESOURCE AVAILABILITY

Lead contact

Requests for further information on software and resources should be directed and will be fulfilled by the lead contact, Jakob N. Kather (jakob-nikolas.kather@alumni.dkfz.de).

Materials availability

This study did not generate new unique reagents.

Data and code availability

The DACHS and QUASAR data used in this study cannot be deposited in a public repository because of local ethical prohibitions. All source codes are available at GitHub: https://github.com/KatherLab/marugoto. Heatmaps for typical patients and high-resolution images of top tiles have been deposited at Zenodo at Zenodo: https://github.com/KatherLab/marugoto. Heatmaps for typical patients and high-resolution images of top tiles have been deposited at Zenodo at Zenodo: https://github.com/KatherLab/marugoto. Heatmaps for typical patients and high-resolution images of top tiles have been deposited at Zenodo at Zenodo: https://doi.org/10.5281/zenodo.7454743. Models trained in this study have been deposited to GitHub: https://github.com/KatherLab/crc-models-2022. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Ethics statement

This study was performed in accordance with the Declaration of Helsinki. This study is a retrospective analysis of digital images of anonymized archival tissue samples of multiple cohorts of CRC patients. Data were collected and anonymized and ethical approval was obtained. The use of tissue samples from QUASAR⁴⁷ was approved by the North East – York Research Ethics Committee (08/H0903/62). DACHS was approved by the Ethics committee of the Medical Faculty at Heidelberg University (310/2001).⁴⁸

Patient cohorts

QUASAR is the "Quick and Simple and Reliable" trial (Yorkshire, UK), which investigated treatment efficacy in patients from the United Kingdom with mostly stage II colorectal tumors.^{47,49} DACHS (Darmkrebs: Chancen der Verhütung durch Screening, Southwest Germany)^{50,51} is a population-based case-control and patient cohort study on CRC including samples from patients of all tumor stages (I-IV) collected from different laboratories in the south-west of Germany coordinated by the German Cancer Research Center (Heidelberg, Germany). In QUASAR, mismatch-repair deficiency (dMMR) or proficiency (pMMR) was determined with immunohisto-chemistry on tissue microarrays (two-plex for MLH1 and MSH2).²¹ Mutational data for *BRAF, KRAS, NRAS,* and PIK3CA was obtained via pyrosequencing.⁵² In DACHS, MSI status was determined with a three-plex PCR assay using the mononucleotide markers BAT25, BAT26, and CAT25 in tissue sections of the paraffin-embedded tumor block. In previous work, this marker panel was shown to differentiate MSI-high from non-MSI-high tumors with a 100% concordance of MSI-high tumors compared with the National Cancer Institute/International Collaborative Group on HNPCC (NCI/ICG-HNPCC) marker panel, which includes the five markers BAT25, BAT26, D17S250, D2S123, and D5S346.^{53,54} Mutational data for KRAS and BRAF was obtained by various methods



in subsets of this multicenter study. In detail, the methods were the single-stranded conformational polymorphism technique and immunohistochemical analyses,⁵⁵ respectively, or by Sanger sequencing.⁵⁶ CONSORT charts with details on missing data and preprocessing drop out for the QUASAR and DACHS cohort can be found in Figures S1 and S2.

METHOD DETAILS

Image preprocessing

All images from H&E stained resection tissue slides were preprocessed according to the "Aachen protocol for deep learning histopathology".⁵⁷ WSIs were tessellated into 512x512 pixels image tiles of 256 µm edge length. Tissue regions were automatically selected using RGB thresholding (summed median brightness across RGB channels < 660) and canny edge detection by requiring at least four edges per image tile.⁴⁰ All remaining tiles were included in the analysis. The fraction of blurry or homogenous tiles was estimated using the method of variation of the Laplacian,⁵⁸ which showed that 9.2% and 3.4% of the tiles stayed below a score value of 80 in the QUASAR and DACHS cohorts, respectively. Tiles were processed at 224 px edge length (effective resolution of 1.14 µm per pixel) using bilinear interpolation as implemented in PyTorch's "Resize" function and normalized with ImageNet's mean and standard deviation of RGB pixel values. Tiles in the training set were color-normalized with Macenko's method using a reference image tile.^{7,59} In the test set, the performance of models was assessed in color-normalized and native tiles.

Biomarker prediction from whole slide images

We compare results obtained with two different DL approaches – the INPT approach against the attMIL approach. Both approaches address a classification problem in which the objective is to predict a slide label from a collection of individual tiles.

In the INPT approach,^{7,30} a DL network pre-trained on ImageNet is fine-tuned using the WSI-level label assigned to each tumor tile. Slide-level predictions are then obtained by averaging/mean-pooling of tile-level predictions. This has resulted in high-performance models,⁹ but imperfect generalization to external cohorts.²¹

The attMIL approach is a two-stage process: First, images of tiles are compressed to image feature vectors using a pre-trained encoder network. Second, the image feature vectors are used as input to a network that uses an attention mechanism for aggregation of predictions from tile to slide level. In short, this network computes an attention-weighted average of the input feature vectors which is then classified and can thus learn which parts of the input image should be discarded for the final prediction. We trained and tested models on top of two publicly available frozen encoders trained with self-supervised learning (SSL), referring to the generic pipeline as "SSL-attMIL". Ciga et al. applied SimCLR⁶⁰ to train a ResNet-18 on 400,000 pathology images selected from 57 datasets.⁶¹ Wang et al. trained a ResNet-50 on a total of 15 million pathology images retrieved from 32,000 WSIs from the full TCGA and PAIP dataset via a clustering-guided contrastive learning (CCL) SSL algorithm.⁶² In CCL, the learning objective is to minimize the contrastive loss between any two tiles from the same WSI and to maximize the loss for any two tiles from different WSIs.⁶² In SimCLR, the contrastive loss is minimized for the same tile and maximized between any two different tiles.⁶⁰ We used both pre-trained models to extract 1024 ("Ciga-attMIL") and 2048 ("Wang-attMIL") features per tile. The set of features from all or a large subset of tiles from a WSI (we randomly sampled 512 every epoch per WSI) was then used as input to the basic attMIL model³² that learns to predict a single label for a WSI.

Finally, we extended the basic attMIL approach by adding basic clinicopathological data as an additional input to the model. These input data are known to be associated with MSI status:²⁴ gender, age, tumor sidedness (lef/right) and organ (colon/rectum) (Table 2). To this end, each patient's clinical data was embedded into a vector representation. For each tile, this clinical data vector was concatenated with the image feature vector.

Setting all values of the image feature vectors to zero results in yet another model that solely depends on clinical data. We call the two described model architectures the "multi-input" and "solely clinical-data-based" models. The multi-input and solely clinical-data-based models were trained using the same hyperparameters as in the image-only approach. Detailed information on the training procedure and model details are available in the STAR Methods.

Visualization and explainability

Visualization of important morphological features relevant to the decision-making processes of DL models is important for: 1) Finding if there are distinct morphologies for various mutations and 2) better comprehension of model internals. For visualization, we used three approaches. We showed the highest-scoring tiles from patients that are correctly classified with the highest scores.⁶³ Additionally, we apply Grad-CAM,⁶⁴ a generalization of the class activation mapping (CAM) algorithm.⁶⁵ Finally, WSI heatmaps display separate spatial distributions of the attention and prediction scores.

Implementation of the INPT approach

In our implementation, tiles were direct inputs for transfer learning. Transfer learning requires a convolutional neural network (ResNet-18) that was pre-trained on ImageNet combined with appropriate substitution for the fully connected classification head. First, the new head's weights are trained with all other layers' weights frozen; subsequently, the remaining layers' weights are unfrozen and fine-tuned. Thus the network learns to predict the biomarker status for a single tile, and the patient score is calculated by averaging across all tiles for a given patient. We used our in-house open-source pipeline DeepMed⁶⁶ with a batch size of 92, the Adam optimizer



 $(\beta_1 = 0.9, \beta_2 = 0.99, \varepsilon = 10^{-5})$, and a learning rate of 2e-3 and 1% weight decay.⁶⁷ The cross-entropy loss function was weighted by the inverse of class frequencies to account for class imbalances. After fine-tuning the model's head for one epoch, the full model was trained for 32 epochs during which the learning rate was scheduled by a modified "1 cycle policy" as made available by fastAl⁶⁸⁻⁷⁰ Maximum learning rates were set in equally spaced slices from lr_max=1e-3 for the deepest layer to lr_max/100 for the shallowest layer, respectively. The learning rates sinusoidally increased from 1/5 of the maxima to the maxima over ten epochs. Then, the learning rates were sinusoidally decreased from the maxima to 1/10,000 of the maxima over the remaining epochs. At the same time, β_1 was sinusoidally varied from 0.95 to 0.85 over the first ten and back to 0.95 over the remaining epochs. During training, tiles in the training data set were augmented by combined operations of random rotations up to 360° with 75 % and vertical flips with 50 % probability.

Implementation of attention-based multiple instance learning

In both self-supervised learning-attMIL approaches, a fully connected layer followed by ReLU embeds the features in a 256-dimensional space. This embedded vector is then passed through a linear layer that outputs another 256-dimensional vector h_k for tile k. Then the attention score a_k for the k-th tile is calculated via:

$$a_{k} = \frac{exp\{w^{T} tanh(Vh_{k})\}}{\sum\limits_{j=1}^{K} exp\{w^{T} tanh(Vh_{j})\}}$$
(Equation 1)

where $h \in R^{256}$, $V \in R^{128\times 256}$, $w \in R^{128}$ and K is the maximal number of tiles randomly resampled every epoch for each patient. Then the MIL pooling operation is applied via:

$$h_{sum} = \sum_{i=1}^{K} a_i h_i, \qquad (Equation 2)$$

where h_i is the i-th tile's embedding; a maximum of K = 512 tiles were used per patient. To obtain the final probability score for each patient, the batch of h_{sum} s is passed through a BatchNorm1D layer, followed by Dropout layer with p=50%. Then, h_{sum} is passed through a fully connected layer with two output dimensions and finally, a softmax layer is applied to obtain the scores. The batch size was 32 patients, the number of epochs was 32, the maximal learning rate was sinusoidally varied from Ir_max/25 to Ir_max=1e-4 over eight epochs and back to Ir_max/10.000 over the remaining epochs, no learning rate slicing was applied, β_1 was varied with the same periodicity, and other hyperparameters were the same as in the INPT approach.

Implementation of multi-input prediction models

We one-hot encoded the patient's gender and tumor location and added the age (years) as an integer variable. All variables were normalized to be zero-centered with a normal distribution. Missing values were filled using mean-imputation. These features were concatenated with a tile's image feature vector before training. This extended vector was then used as input to the attMIL approach. We performed an ablation study by setting the image features to zero to test the performance of a solely clinical-data-based model separately.

QUANTIFICATION AND STATISTICAL ANALYSIS

Experimental design and statistics

We trained all neural network models on QUASAR via stratified five-fold cross-validation on the level of patients ("within-cohort experiment", for MSI, *BRAF*, *KRAS*, *NRAS*, and *PIK3CA*). Subsequently, we applied all five models to the external validation cohort DACHS (only for MSI and *BRAF*). During cross-validation, a validation subset (25% of the training data) was randomly split off every training set to check for overfitting. The area under the receiver operator characteristics curve (AUROC) and the area under the precision-recall curve (AUPRC) give statistical endpoints in our analysis, the latter being more robust to class imbalance. For clarity, we numbered all of our experiments and summarized the results in Table 1. AUROCs of trained models for internal and for external validation for MSI and *BRAF* status prediction on DACHS are compared using the analysis of variances (ANOVA) test and p-values are listed in Tables S3–S8. In addition to the AUROC, we evaluated the sensitivity and specificity of our models at thresholds of 0.25, 0.5, 0.75, and a threshold giving a 95% in-domain sensitivity. The 95% in-domain sensitivity threshold was obtained by taking the average of each model's 95% sensitivity thresholds on its respective internal test dataset.

Cell Reports Medicine, Volume 4

Supplemental information

Generalizable biomarker prediction from cancer

pathology slides with self-supervised deep

learning: A retrospective multi-centric study

Jan Moritz Niehues, Philip Quirke, Nicholas P. West, Heike I. Grabsch, Marko van Treeck, Yoni Schirris, Gregory P. Veldhuizen, Gordon G.A. Hutchins, Susan D. Richman, Sebastian Foersch, Titus J. Brinker, Junya Fukuoka, Andrey Bychkov, Wataru Uegami, Daniel Truhn, Hermann Brenner, Alexander Brobeil, Michael Hoffmeister, and Jakob Nikolas Kather

QUASAR	ТР	FN	TN	FP	DACHS	ТР	FN	TN	FP
Male	110	17	808	140	Male	80	37	1042	40
Female	107	11	490	86	Female	61	32	718	29
Colon	199	25	875	178	Colon	138	59	1029	48
Rectum	7	2	391	37	Rectum	3	10	731	21
Left	177	19	861	105	Left	126	48	1230	37
Right	24	8	341	101	Right	14	21	511	32
Age	61.4	60.6	62.6	62.2	Age	70.8	69.0	68.7	66.9
Tumor Stage	2.1	2.1	2.1	2.1	Tumor Stage	2.2	2.1	2.5	2.8
BRAF ^{wt}	92	18	895	140	BRAF ^{wt}	70	53	1555	51
BRAF ^{mut}	59	4	30	11	BRAF ^{mut}	62	15	53	11
KRAS ^{wt}	117	12	533	88	KRAS ^{wt}	110	47	1073	51
KRAS ^{mut}	28	8	373	56	KRAS ^{mut}	23	18	553	16
					CIMP	95	39	1560	59
					non-CIMP	46	30	200	10

Supplementary Tables

Table S1: Clinical statistics stratified by MSI biomarker test outcome for patients with CRC in the QUASAR (left) and DACHS (right) cohort at threshold value 0.5, Related to Figure 3. TP = True positive, FN = False negative, TN = True negative, FP = False positives.

QUASAR	ТР	FN	TN	FP	DACHS	ТР	FN	TN	FP
Male	47	18	641	204	Male	81	14	835	318
Female	41	14	357	154	Female	48	8	486	285
Colon	79	25	642	282	Colon	120	17	742	424
Rectum	5	5	309	56	Rectum	9	5	579	179
Left	74	20	650	186	Left	110	15	977	322
Right	8	10	245	145	Right	18	7	330	277
Age	66.0	63.6	62.6	61.0	Age	73.1	73.7	68.5	68.0
Tumor Stage	2.13	2.13	2.1	2.1	Tumor Stage	2.6	1.9	2.3	2.7
MSI	55	20	816	219	MSI	66	11	1135	471
non-MSI	21	8	38	72	nonMSI	55	9	50	73
KRAS ^{wt}	83	28	593	176	KRAS ^{wt}	114	21	803	357

KRAS ^{mut}	2	3	381	167	KRAS ^{mut}	8	21	426	198
					CIMP	82	16	1173	491
					non-CIMP	45	6	139	104

Table S2: Clinical statistics stratified by BRAF biomarker test outcome for patients with CRCin the QUASAR (left) and DACHS (right) cohort at threshold value 0.5, Related to Figure 3. TP= True positive, FN = False negative, TN = True negative, FP = False positives.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0284	0.9526	0.0218	0.0003
Wang+attMIL	0.0284	1	0.0132	0.7316	<0.0001
Ciga+attMIL	0.9526	0.0132	1	0.0103	0.0001
multi-input	0.0218	0.7316	0.0103	1	<0.0001
clinical data only	0.0003	<0.0001	0.0001	<0.0001	1

Table S3: p-values from ANOVA analysis comparing all possible AUROC pairs of MSI modelsinternal validation performances on Macenko normalized tiles in QUASAR, Related to STARMethods.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0069	0.9005	0.0221	0.4404
Wang+attMIL	0.0069	1	0.0346	0.8161	0.1679
Ciga+attMIL	0.9005	0.0346	1	0.0484	0.4796
multi-input	0.0221	0.8161	0.0484	1	0.1747
clinical data only	0.4404	0.1679	0.4796	0.1747	1

Table S4: p-values from ANOVA analysis comparing all possible AUROC pairs of *BRAF* models internal validation performances on Macenko normalized tiles in QUASAR, Related to STAR Methods.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0002	<0.0001	0.0002	0.0001
Wang+attMIL	0.0002	1	<0.0001	0.7009	<0.0001
Ciga+attMIL	<0.0001	<0.0001	1	<0.0001	0.0001
multi-input	0.0002	0.7009	<0.0001	1	<0.0001

clinical data only 0.0001	<0.0001	0.0001	<0.0001	1	
---------------------------	---------	--------	---------	---	--

Table S5: p-values from ANOVA analysis comparing all possible AUROC pairs of MSI modelsvalidation performances on Macenko normalized tiles in DACHS, Related to STAR Methods.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0001	0.0039	<0.0001	0.8309
Wang+attMIL	0.0001	1	<0.0001	0.0316	<0.0001
Ciga+attMIL	0.0039	<0.0001	1	<0.0001	0.0014
multi-input	<0.0001	0.0316	<0.0001	1	<0.0001
clinical data only	0.8309	<0.0001	0.0014	<0.0001	1

Table S6: p-values from ANOVA analysis comparing all possible AUROC pairs of MSI modelsvalidation performances on non-normalized tiles in DACHS, Related to STAR Methods.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0019	0.0021	<0.0001	0.8074
Wang+attMIL	0.0019	1	<0.0001	0.0003	0.031
Ciga+attMIL	0.0021	<0.0001	1	<0.0001	0.0064
multi-input	<0.0001	0.0003	<0.0001	1	0.0006
clinical data only	0.8074	0.031	0.0064	0.0006	1

Table S7: p-values from ANOVA analysis comparing all possible AUROC pairs of *BRAF* models validation performances on Macenko normalized tiles in DACHS, Related to STAR Methods.

	INPT	Wang+attMIL	Ciga+attMIL	multi-input	clinical data only
INPT	1	0.0795	0.0177	<0.0001	0.0804
Wang+attMIL	0.0795	1	0.0038	0.0047	0.977
Ciga+attMIL	0.0177	0.0038	1	0.0002	0.0038
multi-input	<0.0001	0.0047	0.0002	1	0.0041
clinical data only	0.0804	0.977	0.0038	0.0041	1

Table S8: p-values from ANOVA analysis comparing all possible AUROC pairs of BRAF mod-

els validation performances on non-normalized tiles in DACHS, Related to STAR Methods.

Supplementary Figures




Figure S1: CONSORT charts for QUASAR, Related to Table 2 and STAR Methods. (A) MSI status, **(B)** *BRAF* status, **(D)** *KRAS* status, **(D)** *NRAS* status, **(E)** *PIK3CA* status.




Figure S2: CONSORT charts for DACHS, Related to Table 2 and STAR methods. (A) MSI status, **(B)** *BRAF* status.




Figure S3: Precision recall curves (PRC) for the external validation (on QUASAR) of the best model (Wang-attMIL), Related to Table 1. (A) PRC for MSI detection, MSI class. **(B)** PRC for *BRAF* mutation prediction, *BRAF* mutant class, **(C)** PRC for MSI detection, non-MSI (MSS) class, **(D)** PRC for *BRAF* mutation prediction, *BRAF* wild type class. The y-values of the horizontal dotted red lines in A-D denote the fraction of true positives in the data sets and represent the precisions achieved if every patient was classified as positive.




Figure S4: Quantification of the domain shift between internal and external prediction performance for the best image-only models (Wang-attMIL), Related to Table 1. (A) Distribution of model prediction scores for all patients in QUASAR, split by MSI status (ground truth), obtained via cross-validation; scores MSIH: median(m)=0.92, lower quartile(q1)=0.78, upper quartile(q3)=0.98; scores nonMSIH: m=0.169, q1=0.085, q3=0.34. (B) Distribution of model prediction scores for all patients in QUASAR, split by *BRAF* status (ground truth), obtained via cross-validation; scores MUT: m=0.74, q1=0.48, q3 =0.89; scores WT: median=0.32, q1=0.18, q3=0.51. (C) Average MSI score distribution of predictions across all models for patients in DACHS, split by MSI status (ground truth); scores MSIH: m=0.64, q1= 0.43, q3=0.90; scores nonMSIH: m=0.097, q1=0.055, q3=0.18. (D) Average *BRAF* score distribution of predictions across all models for patients in DACHS, split by *BRAF* status (ground truth); scores MUT: m=0.79, q1=0.66, q3=0.88; WT: m=0.37, q1=0.28, q3=0.54. Displayed frequency distributions of the more frequent class (i.e. the negative class) are rescaled to twice the frequency of the less frequent class. For internal validation, summed distributions over all five test sets, and for external validation, averaged distributions over all five models are shown.




Figure S5: Prediction score distribution in internal and external sets for the best model (multiinput model), Related to Taable 1. (A) Distribution of model prediction scores for all patients in QUASAR, split by MSI status (ground truth), obtained via cross-validation; scores MSIH: median(m)=0.94, lower quartile(q1)=0.74, upper quartile(q3)=0.99; scores nonMSIH: m=0.18,q1=0.11, q3=0.32. (B) Distribution of model prediction scores for all patients in QUASAR, split by *BRAF* status (ground truth), obtained via cross-validation; scores MUT: m=0.78, q1=0.49,q3=0.91; scores WT: m=0.34, q1=0.23, q3=0.51. (C) Distribution of model prediction scores for all patients in DACHS, split by MSI status (ground truth), obtained via cross-validation; scores MSIH: m=0.72, q1=0.48, q3=0.94; scores nonMSIH: m=0.12, q1=0.08, q3=0.19. (D) Distribution of model prediction scores for all patients in DACHS, split by *BRAF* status (ground truth), obtained via cross-validation; scores MUT: m=0.79, q1=0.66,q3=0.88; scores WT: m=0.37, q1=0.28, q3=0.54.




Figure S6: Correlation of prediction scores for MSI and *BRAF* **status for the best image-only model (attMIL with Wang features), Related to Figure 5. (A)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSS, BRAF mut. **(B)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSI, *BRAF* mut. **(C)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSI, *BRAF* mut. **(C)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSS, *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSS, *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSS, *BRAF* wild type. **(D)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSI, *BRAF* wild type. **(D)** Correlation of MSI (vertical axis) and *BRAF* (horizontal axis) prediction score for patients with ground truth status: MSI, *BRAF* wild type.